



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 259 632 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

- (49) Date of publication of patent specification: **13.12.95** (51) Int. Cl.<sup>6</sup>: **C12N 15/16**, C12N 15/48,  
C12N 15/81, C12P 21/02,  
(21) Application number: **87111591.1** A61K 38/00  
(22) Date of filing: **11.08.87**

The file contains technical information submitted  
after the application was filed and not included in  
this specification

### (54) Expression of biologically active PDGF analogs in eucaryotic cells

- (30) Priority: **13.08.86 US 896485**  
**15.12.86 US 942161**  
**15.12.86 US 942484**  
**15.12.86 US 941970**

- (43) Date of publication of application:  
**16.03.88 Bulletin 88/11**

- (49) Publication of the grant of the patent:  
**13.12.95 Bulletin 95/50**

- (84) Designated Contracting States:  
**AT BE CH DE FR GB IT LI LU NL SE**

- (56) References cited:  
**EP-A- 0 171 142**  
**EP-A- 0 177 957**

**BIOLOGICAL ABSTRACTS /RRM Philadelphia**  
**PA(US); E.W. RAINES et al., no.**

**BIOLOGICAL ABSTRACTS RRM Philadelphia,**  
**PA (US); K.H. SPRUGEL et al., no. 30041507**  
**&NUM;**

**NATURE,vol.319,p.511-14,1986**

**EMBO JOURNAL,vol.12,no.3,p.2963-67,1984**

- (73) Proprietor: **ZYMOGENETICS, INC.**  
**4225 Roosevelt Way, N.E.**  
**Seattle, WA 98105 (US)**

- (72) Inventor: **Murray, Mark J.**  
**2211, 11th Avenue East**  
**Seattle, WA 98102 (US)**  
Inventor: **Kelly, James D.**  
**124 N.E. 51st Street**  
**Seattle, WA 98105 (US)**

- (74) Representative: **Jorgensen, Dan et al**  
**Novo Nordisk A/S,**  
**Patent Department,**  
**Novo Allé**  
**DK-2880 Bagsvaerd (DK)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**EP 0 259 632 B1**

**Description**Technical Field

5 The present invention relates to the production of PDGF analogs in general, and more specifically, to the expression of biologically active PDGF analogs in eucaryotes.

Background Art

10 Human platelet-derived growth factor (PDGF) has been shown to be the major mitogenic protein in serum for mesenchymal derived cells. This is well documented by numerous studies of platelet extracts or purified PDGF induction of either cell multiplication or DNA synthesis (a prerequisite for cell division) in cultured smooth muscle cells, fibroblasts and glial cells (Ross et al., *PNAS* 71: 1207, 1974; Kohler and Lipton, *Exp. Cell Res.* 87: 297, 1974; Westermarck and Wasteson, *Exp. Cell Res.* 98: 170, 1976; Heldin et al.,  
15 *J. Cell Physiol.* 105: 235, 1980; Raines and Ross, *J. Biol. Chem.* 257: 5154, 1982). Furthermore, PDGF is a potent chemoattractant for cells that are responsive to it as a mitogen (Grotendorst et al., *J. Cell Physiol.* 113: 261, 1982; Seppa et al., *J. Cell Biol.* 92: 584, 1982). It is not generally the case that mitogens also act as chemotactic agents. Due to its mitogenic activity, PDGF is useful as an important component of a defined medium for the growth of mammalian cells in culture, making it a valuable research reagent with  
20 multiple applications in the study of animal cell biology.

*In vivo*, PDGF normally circulates stored in the alpha granules of platelets. Injury to arterial endothelial linings causes platelets to adhere to the exposed connective tissue and release their granules. The released PDGF is thought to chemotactically attract fibroblasts and smooth muscle cells to the site of injury and to induce their focal proliferation as part of the process of wound repair (Ross and Glomset, *N. Eng. J. of Med.*  
25 295: 369, 1976).

It has been postulated that as a part of this response to injury, PDGF released by platelets may play a causative role in the development of the proliferative lesions of atherosclerosis (Ross and Glomset, *ibid.*) which is one of the principal causes of myocardial and cerebral infarction. Strategies for the prophylaxis and treatment of atherogenesis in the past have been narrowly directed toward reducing risk factors for the  
30 disease, such as lowering blood pressure in hypertensive subjects and reducing elevated cholesterol levels in hypercholesterolemic subjects.

Recent studies have shown that at least one of the two protein chains comprising PDGF and the putative transforming protein of simian sarcoma virus (SSV), an acute transforming retrovirus, appear to have arisen from the same or closely related cellular genes. In particular, computer analysis of a partial  
35 amino acid sequence of PDGF has revealed extensive homology with the gene product, p28<sup>sis</sup>, of SSV (Doolittle et al., *Science* 221: 275, 1983; Waterfield et al., *Nature* 304: 35, 1984; and Johnson et al., *EMBO J.* 3: 921, 1984). Further, more recent studies have illustrated that p28<sup>sis</sup> and PDGF show antigenic as well as structural similarities (Robbins et al., *Nature* 305: 605, 1983; Niman, *Nature* 307: 180, 1984).

It has been established that porcine PDGF bears antigenic determinants in common with human PDGF.  
40 However, in other respects porcine PDGF is clearly different from human PDGF. Thus, the apparent molecular weight, as determined on SDS gels for the porcine molecule is 38,000 Daltons compared with a range centered around 30,000 Daltons for human PDGF (Stroobant et al., *EMBO J.* 3: 2963, 1984).

A growth factor which is a homodimer of polypeptide chains structurally related to the human PDGF A chain has been isolated from a human osteosarcoma cell line (Heldin et al., *Nature* 319: 511, 1986).

45 No mitogenic activity could be detected with a B chain monomer in a study which suggested that a PDGF B chain homodimer may be an active mitogen in platelets and that the A chain is not required (Kelly et al., *EMBO J.* 4: 3399, 1985).

European Patent Application having the publication No. 177 957 discloses a DNA construct capable of directing the expression and secretion of biologically active PDGF analogs in eucaryotic cells, a method  
50 of preparing such analogs, and a method of promoting the growth of mammalian cells by means of such analogs.

Although previous attempts, such as that summarized in Devare et al. (*Cell* 36: 43, 1984), have been made to express the v-sis gene in a transformed microorganism, they have not been successful in producing mitogenic material. More recently, investigators have described the production of p28<sup>sis</sup> in *E. coli*  
55 as a fusion protein (Wang et al., *J. Biol. Chem.* 259: 10645, 1984). This protein appears to compete with PDGF for binding to PDGF receptor sites. While SSV transformed rodent cells have been shown to exhibit a mitogenic activity similar to PDGF (Deuel et al., *Science* 221: 1348, 1983; Owen et al., *Science* 225: 54, 1984), it is not clear that this activity is due to a gene product from SSV (i.e., p28<sup>sis</sup>). Furthermore, cells

transformed by a variety of viruses other than SSV produce a PDGF-like mitogen into the culture medium (Bowen-Pope et al., PNAS 81: 2396, 1984).

While natural PDGF may be isolated from human plasma or platelets as starting material, it is a complex and expensive process, in part due to the limited availability of the starting material. In addition, it is difficult to purify PDGF with high yield from other serum components due to its extremely low abundance and biochemical properties. Furthermore, the therapeutic use of products derived from human blood carries the risk of disease transmission due to contamination by, for example, hepatitis virus, cytomegalovirus, or HIV.

In view of PDGF's clinical applicability in the treatment of injuries in which healing requires the proliferation of fibroblasts or smooth muscle cells and its value as an important component of a defined medium for the growth of mammalian cells in culture, the production of useful quantities of protein molecules similar to authentic PDGF which possess mitogenic activity is clearly invaluable.

In addition, the ability to produce relatively large amounts of PDGF or PDGF analogs would be a useful tool for elucidating the putative role of the v-sis protein, p28<sup>sis</sup>, in the neoplastic process.

Further, since local accumulation of smooth muscle cells in the intimal layer of an arterial wall is central to the development of atherosclerotic lesions (Ross and Glomset, *ibid.*), one strategy for the prophylaxis and treatment of atherosclerosis would be to suppress smooth muscle cell proliferation. The ability to produce large amounts of PDGF would be useful in developing inhibitors or designing specific approaches which prevent or interfere with the in vivo activity of PDGF in individuals with atherosclerosis.

#### Disclosure of the Invention

Briefly stated, the present invention discloses methods for expressing a variety of biologically active PDGF analogs in eucaryotic cells. In general, the methods comprise introducing into a eucaryotic host cell a DNA construct capable of directing the expression and secretion of biologically active PDGF analogs in eucaryotic cells. The DNA construct contains a transcriptional promoter followed downstream by an appropriate DNA sequence.

In one aspect of the present invention there is provided a recombinant protein homodimer having two disulfide-bonded polypeptide chains, said chains selected from the group consisting of:

- (a) the A-chain of human PDGF from amino acid 9 to amino acid 104;
- (b) the A chain of human PDGF from amino acid 9 to amino acid 95;
- (c) the A-chain of human PDGF from amino acid 1 to amino acid 95; and
- (d) the A-chain of human PDGF from amino acid 1 to amino acid 104,

said protein having human PDGF mitogenic activity. In a preferred embodiment of the invention at least one cysteine residue at position 37, 46 or 47 of said protein is substituted by another amino acid residue. Preferably, this other amino acid residue is a serine residue.

In another aspect of the present invention there is provided a recombinant protein having two disulfide-bonded polypeptide chains, wherein at least one of said chains is a mosaic of amino acid sequences of the A- and B-chains of human PDGF, wherein the mosaic chain is selected from the group consisting of:

- (a) A-chain amino acids 1-17 joined to B-chain amino acids 24-109;
- (b) A-chain amino acids 1-31 joined to B-chain amino acids 38-109;
- (c) A-chain amino acids 1-17 joined to B-chain amino acids 24-97 joined to A-chain amino acids 92-104; and wherein the second chain is selected from the group consisting of: chains (a), (b) and (c) as defined above;
- (d) the A-chain of human PDGF from amino acid 9 to amino acid 104;
- (e) the A chain of human PDGF from amino acid 9 to amino acid 95;
- (f) the A-chain of human PDGF from amino acid 1 to amino acid 95;
- (g) the A-chain of human PDGF from amino acid 1 to amino acid 104;
- (h) the B-chain of human PDGF from amino acid 15 to amino acid 109;
- (i) the B-chain of human PDGF from amino acid 1 to amino acid 101;
- (j) the B-chain of human PDGF from amino acid 15 to amino acid 101; and
- (k) the B-chain of human PDGF from amino acid 1 to amino acid 109,

said protein having human PDGF mitogenic activity. In another preferred embodiment of the invention at least one cysteine residue at a position corresponding to A-chain position 37, A-chain position 46, A-chain position 47, B-chain position 43, B-chain position 52 or B-chain position 53 is substituted by another amino acid residue. Preferably, this other amino acid residue is a serine residue.

Preferably, the recombinant protein according to the present invention is unglycosylated.

In a further aspect, the present invention relates to a therapeutic composition comprising a recombinant protein according to the invention and a physiologically acceptable carrier. Preferred examples of carriers are albumin, sterile water, and saline. The therapeutic composition according to the invention may further comprise an adjuvant. Preferably, said adjuvant is selected from collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic. Preferably, the protein of the invention is present in the therapeutic composition in a concentration of from 1 to 50 µg/ml of total volume.

In a further aspect of the present invention the therapeutic composition comprising the protein of the invention is used in enhancing the wound-healing process in warm-blooded animals.

In a further aspect of the present invention, a protein according to the invention is used in promoting the growth of mammalian cells by incubating the cells with the protein.

In a further aspect, the present invention relates to a wound dressing containing a protein according to the invention.

In a further aspect, the present invention relates to the use of a protein according to the invention for the manufacture of a medicament for enhancing the wound-healing process in warm-blooded animals.

In a further aspect, the present invention relates to a DNA construct capable of directing the expression and secretion in eucaryotic cells of a polypeptide selected from the group consisting of:

- (a) the A-chain of human PDGF from amino acid 9 to amino acid 104;
- (b) the A-chain of human PDGF from amino acid 9 to amino acid 95;
- (c) the A-chain of human PDGF from amino acid 1 to amino acid 95;
- (d) the A-chain of human PDGF from amino acid 1 to amino acid 104.

In a preferred embodiment, at least one cysteine residue at a position corresponding to A-chain position 37, 46 or 47 in the encoded protein is substituted by another amino acid residue. Preferably, this other amino acid residue is a serine residue.

In a further aspect, the present invention relates to a DNA construct capable of directing the expression and secretion of biologically active human PDGF analogs in eucaryotic cells, said DNA construct containing a transcriptional promoter followed downstream by a DNA sequence encoding a polypeptide which is a mosaic of amino acid sequences of the A- and B-chains of human PDGF, wherein said polypeptide is selected from the group consisting of:

- (a) A-chain amino acids 1-17 joined to B-chain amino acids 24-109;
- (b) A-chain amino acids 1-31 joined to B-chain amino acids 38-109;
- (c) A-chain amino acids 1-17 joined to B-chain amino acids 24-97 joined to A-chain amino acids 92-104.

In a preferred embodiment, at least one cysteine residue at a position corresponding to B-chain position 43, 52 or 53 is substituted by another amino acid residue. Preferably, this other amino acid residue is a serine residue.

In a further aspect, the polypeptide encoded by the DNA construct of the invention does not include an N-linked glycosylation site.

In a further aspect, the present invention relates to a method of preparing biologically active human PDGF analogs, comprising:

- introducing into a eucaryotic host cell a DNA construct according to the invention;
- growing said eucaryotic host cell in an appropriate medium; and
- isolating the PDGF analog from said eucaryotic host.

In a further aspect, the present invention relates to a method of preparing biologically active human PDGF analogs, comprising:

- introducing into a eucaryotic host cell a DNA construct according to claim 19;

introducing into said eucaryotic host cell a second DNA construct containing a transcriptional promoter followed downstream by a DNA sequence encoding a polypeptide selected from the group consisting of:

- (a) the A-chain of human PDGF from amino acid 9 to amino acid 104;
- (b) the A-chain of human PDGF from amino acid 9 to amino acid 95;
- (c) the A-chain of human PDGF from amino acid 1 to amino acid 95;
- (d) the A-chain of human PDGF from amino acid 1 to amino acid 104.
- (e) the B-chain of human PDGF from amino acid 15 to amino acid 109;
- (f) the B-chain of human PDGF from amino acid 1 to amino acid 101;
- (g) the B-chain of human PDGF from amino acid 15 to amino acid 101;
- (h) the B-chain of human PDGF from amino acid 1 to amino acid 109;

- growing said eucaryotic host cell in an appropriate medium; and
- isolating the PDGF analog from said eucaryotic host.

Other aspects of the invention will become evident upon reference to the following detailed description and attached drawings.

Brief Description of the Drawings

Figure 1A is a schematic restriction map of the proviral genome of SSV.

Figure 1B depicts the nucleotide sequence and predicted amino acid sequence encoded by the v-sis  
5 region of the SSV genome.

Figure 2 illustrates the construction of a plasmid which contains the MF $\alpha$ 1 promoter and secretory signal sequence upstream of the v-sis gene.

Figure 3 illustrates the construction of plasmid p192.

Figure 4 illustrates the oligonucleotide-directed deletion mutagenesis of the amino terminal 66 v-sis  
10 codons.

Figure 5 illustrates the construction of plasmid p270.

Figure 6 illustrates the insertion of v-sis expression units upstream of the TPI1 terminator.

Figure 7 illustrates the construction of plasmid pTVS2 $\alpha$ T.

Figure 8 illustrates the construction of a B-chain expression unit VSB and its introduction into the  
15 pMPOT2 vector.

Figure 9 depicts the amino acid sequences of the mature A- and B-chains of PDGF.

Figure 10 is a dose response curve of PDGF receptor binding by media concentrates from yeast transformants containing plasmids pVSBm and pMPOT2 compared to authentic PDGF.

20 Best Mode For Carrying Out the Invention

Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms to be used hereinafter.

Polypeptide: A polymer of amino acids.

25 Reading Frame: The arrangement of nucleotide codons which encode an uninterrupted stretch of amino acids. During translation of an mRNA, the proper reading frame must be maintained. For example, the sequence GCUGGUUGUAAG may be translated into three reading frames or phases, depending on whether one starts with G, with C, or with U, and thus may yield three different peptide products. Translation of the template begins with an AUG codon, continues with codons for specific amino acids, and terminates with  
30 one of the translation termination codons.

Coding Sequence: DNA sequences which in the appropriate reading frame directly code for the amino acids of a protein.

Complementary DNA: or cDNA. A DNA molecule or sequence which has been enzymatically synthesized from the sequences present in an mRNA template, or a clone of such a molecule.

35 Secretory Signal Sequence: That portion of a gene or cDNA encoding a signal peptide. A signal peptide is the amino acid sequence in a secretory protein which signals its translocation into the secretory pathway of the cell. Signal peptides generally occur at the beginning (amino terminus) of the protein and are approximately 20-40 amino acids long with a stretch of about 9-10 hydrophobic amino acids near the center. Very often the signal sequence is proteolytically cleaved from the protein during the process of  
40 secretion.

Cell Surface Receptor: A protein molecule at the surface of a cell which specifically interacts with or binds a molecule approaching the cell's surface. Once the receptor has bound the cognate molecule, it effects specific changes in the physiology of the cell.

45 Mitogen: A molecule which stimulates cells to undergo mitosis. Mitosis is asexual somatic cell division leading to two daughter cells, each having the same number of chromosomes as the parent cell.

Transformation: The process of stably and hereditably altering the genotype of a recipient cell or microorganism by the introduction of purified DNA. This is typically detected by a change in the phenotype of the recipient organism.

Transcription: The process of producing a mRNA template from a structural gene.

50 Expression: The process, starting with a structural gene or cDNA, of producing its polypeptide, being a combination of transcription and translation. An expression vector is a plasmid-derived construction designed to enable the expression of a gene or cDNA carried on the vector.

55 Plasmid: An extrachromosomal, double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics of that organism may be changed or transformed as a result of the expression of the DNA sequences of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (tet<sup>R</sup>) transforms a cell previously sensitive to tetracycline into one which is resistant to it.

Yeast Promoter: DNA sequences upstream from a yeast gene which promote its transcription.

Biological Activity: Some function or set of activities performed by a molecule in a biological context (i.e., in an organism or an *in vitro* facsimile). In the case of PDGF, these biological activities include the induction of chemotaxis and/or mitogenesis of responsive cell types, following the binding of PDGF to specific cell surface receptors. Other biological effects of human platelet PDGF may include: phospholipase activation; increased phosphatidylinositol turnover and prostaglandin metabolism; stimulation of both collagen and collagenase synthesis by responsive cells; an indirect proliferative response of cells lacking PDGF receptors; and potent vasoconstrictor activity.

PDGF Analog: A polypeptide which is substantially homologous to at least a portion of the A-chain or the B-chain of PDGF, or both, wherein the polypeptide exhibits biological activity as defined herein.

As noted above, human platelet-derived growth factor (PDGF) has been shown to be a major mitogen in serum. PDGF, as it is isolated from platelets, is a different molecule from the novel proteins of the present invention. PDGF is known to be composed of two polypeptide chains, an A-chain and a B-chain, which are held together by disulfide bonds to form the biologically active heterodimer molecule. This structure has been confirmed by immunoprecipitation experiments (Hart et al., Heldin et al., unpublished). These investigators used monoclonal antibodies directed specifically against the A-chain or the B-chain to immunoprecipitate PDGF. Their results indicate that the PDGF can be removed from solution with antibodies which recognize either chain alone. This confirms the structure of PDGF as a heterodimer of two different polypeptide chains. In addition, naturally-occurring PDGF contains carbohydrate (Deuel et al., J. Biol. Chem. 256: 8896-8899, 1981). Following complete chemical reduction, the single polypeptide chains alone do not exhibit any mitogenic activity (Raines and Ross, *ibid.*), and attempts to reconstitute activity by reoxidation of the reduced polypeptides have not been successful. Recently, the amino acid sequence of the B-chain has been determined and shown to be substantially homologous to a portion of the v-sis gene product, p28<sup>sis</sup> (Doolittle et al., *ibid.*; Waterfield et al., *ibid.*; and Johnson et al., *ibid.*). The homology between these two proteins strongly suggests that they are derived from the same or closely related cellular genes.

Given the fact that a single reduced A-chain or B-chain polypeptide is not biologically active and that previous attempts directed toward expressing v-sis sequences in *E. coli* did not yield mitogenic material, it would not be expected that merely expressing a sequence encoding a PDGF-like molecule in a microorganism would result in a molecule which exhibited biological activity.

The present invention, however, unlike the previous attempts noted above, unexpectedly provides for the expression of DNA sequences encoding PDGF A-chain or B-chain, variants or derivatives of the A- and B-chains, as well as mosaics of portions of the A- and B-chains or their derivatives, in a manner that the expressed molecules exhibit biological activity characteristic of PDGF. Further, the expression system of the present invention was designed to produce the gene product via a eucaryotic secretory pathway. This enables the expressed polypeptide molecules to be properly processed, correctly folded and assembled into biologically active dimers. Indeed, the present invention, in contrast to previous efforts, results in the secretion of PDGF-like dimers which are biologically active in established assays for PDGF activity, i.e., radioreceptor assay (RRA), mitogenesis assay, and chemotaxis assay.

In its biologically active form, PDGF is a heat-stable protein composed of heterogeneously sized species ranging between 28,000 and 31,000 Daltons, all of the individual species being active in stimulating DNA synthesis (Raines and Ross, *ibid.*; Deuel et al., J. Biol. Chem. 256: 8896, 1981; Antoniades, PNAS 78: 7314, 1981). Where individual species with molecular sizes of 27,000; 28,500; 29,000; and 31,000 Daltons have been isolated and analyzed, they show extensive tryptic peptide homology and have been found to have comparable mitogenic activity and amino acid composition (Raines and Ross, *ibid.*). The slight variations in size among the species are most probably due to differences in carbohydrate composition and minor proteolysis.

Through studies of PDGF which has been extensively purified from platelet-rich human plasma, it is likely, as noted above, that PDGF is composed of two polypeptide chains, an A-chain (14,000 Daltons) and a B-chain (16,000 Daltons), which are disulfide bonded together to form the biologically active dimer molecule (Raines and Ross; Deuel et al.; Antoniades, *ibid.*). The PDGF nomenclature found in the literature is not consistent (Doolittle et al.; Waterfield et al.; Raines and Ross; Johnsson et al., *ibid.*). The nomenclature of Johnsson et al. (*ibid.*), wherein the two polypeptides found in pure PDGF are called "A-chain" and "B-chain," is adopted herein. The B-chain is homologous to p28<sup>sis</sup> and was previously called "peptide I" (Waterfield et al., *ibid.*) or "1a" (Doolittle et al., *ibid.*). The A-chain was previously termed "peptide II" (Waterfield et al., *ibid.*) or "2a" (Doolittle et al., *ibid.*). Data derived from a partial amino acid sequence of PDGF indicate that the two polypeptide chains (A-chain and B-chain) show extensive homology (Doolittle et al., *ibid.*; Waterfield et al., *ibid.*; and Johnsson et al., *ibid.*; Antoniades and Hunkapiller, Science 220: 963, 1983). More specifically, it has been reported that there is 56% amino acid identity between the

two chains. In addition, as shown in Figure 9, there are several blocks of perfect homology between the two chains. Further, both of the chains contain eight cysteine residues at identical positions, suggesting that each polypeptide folds into a similar three-dimensional structure.

It appears that these two polypeptides are closely related members of a small family. The blocks of perfect homology between the A- and B-chains reflect regions of the protein which may contribute to function, while the less homologous regions may reflect portions of the protein which are less important to its function. Therefore, as further exemplified by the present invention, certain portions of either the A- or B-chains may be deleted or substituted, while retaining biological activity within the resultant protein.

Based upon the teachings of the present invention, the homology between the A- and B-chains, together with the coincidence of cysteine residues, one skilled in the art can design additional suitable members of this homologous family. For example, one skilled in the art could construct a variety of hybrids between the A- and B-chain genes which would encode proteins in which the homologous domain structures were preserved. It is demonstrated herein that these proteins can be expected to assume a three-dimensional structure similar to wild-type A- or B-chains and retain biological activity.

The v-sis gene, as mentioned above, is the transforming gene of simian sarcoma virus (SSV). The v-sis gene has been cloned and its DNA sequence determined (Devare et al., *PNAS* 79: 3179, 1982; Devare et al., *PNAS* 80: 731, 1983). Analysis of this sequence revealed an open reading frame which could encode a 28,000 Dalton protein, designated p28<sup>sis</sup>. Subsequently, such a protein was immunologically identified in SSV-infected cells (Niman, *ibid.*; Robbins, *ibid.*). The predicted amino acid sequence of the v-sis gene product, p28<sup>sis</sup>, was found to have a high degree of homology with the actual amino acid sequence of a portion of the B-chain of PDGF (Johnsson, *ibid.*). The homology of the PDGF B-chain to the v-sis gene product begins at amino acid 67 of p28<sup>sis</sup>, a serine, and continues for 109 amino acids to a threonine residue at amino acid 175. The amino acid sequences preceding and following the B-chain homologous region of p28<sup>sis</sup> are not homologous to either the A- or B-chains of mature PDGF (Johnsson, *ibid.*) and represent portions of the B-chain precursor. In addition, PDGF and p28<sup>sis</sup> have been shown to be similar antigenically (Niman, *ibid.*; Robbins, *ibid.*). The v-sis gene product, p28<sup>sis</sup>, a protein of approximately 226 amino acids, dimerizes and is proteolytically processed to a protein of approximately 20,000 Daltons (p20<sup>sis</sup>) in SSV infected cells (Niman, *ibid.*; Robbins, *ibid.*). This 20,000 Dalton protein can be immunoprecipitated with antiserum against PDGF.

The mature B-chain homologous region of v-sis encodes a 109 amino acid polypeptide which is almost identical to the human B-chain. The four amino acid differences between these two gene products occur at positions 6, 7, 91 and 97. The mature human A-chain sequence is 104 amino acids in length, and is 56 percent homologous to the B-chain, therefore having a degree of homology to the v-sis product similar to its homology to the B-chain.

In contrast to naturally-occurring PDGF, one particular aspect of this present invention discloses protein products that are disulfide-bonded dimers of two A-chain-like polypeptides. One such dimer, comprising chains having complete homology to the 104 amino acids of PDGF A-chain, migrates on polyacrylamide gels with an apparent molecular weight of ca. 31,000 Daltons. When the dimer is chemically reduced, the component chains migrate to a position consistent with a polypeptide of 104 amino acids. The amino acid composition of the pure protein has been determined and the results show that the composition is substantially identical to the A-chain sequence shown in Figure 9. The amino acid sequence of this pure, yeast-expressed protein was determined using a gas-phase sequenator (Applied Biosystems). All of the amino terminal sequence obtained could be accounted for by the sequence information shown for the A-chain in Figure 9. These results indicate that the proteins of this aspect of the present invention are homodimers consisting of polypeptide chains homologous to the A-chain of PDGF. The amino acid sequence of the A-chain produced in yeast contained no N-linked glycosylation sites. The glycosylation site present in the native human A-chain was purposely omitted from this construction in order to avoid yeast carbohydrate addition. There is no evidence, based on polyacrylamide gel electrophoresis, that the yeast-expressed A-chain contains carbohydrate. The biological activity observed for these unglycosylated PDGF analogs is somewhat surprising in view of the dependence on glycosylation for biological activity associated with several glycoprotein hormones and other growth factors.

As noted above, another aspect of the present invention discloses proteins comprising polypeptides which are variants and derivatives of the A-chain or B-chain of PDGF. These modifications fall basically into two classes: amino acid deletions and amino acid substitutions, including the cysteine and phenylalanine substitutions discussed below.

In regard to the deletion of amino acids, it has been found that the PDGF A-chain and B-chain may be truncated at either or both the amino- and carboxy-terminal ends and will still form biologically active molecules. Removal of these amino- and/or carboxy-terminal amino acids results in smaller biologically

active molecules, which may have broader therapeutic utility. Amino acids which may be deleted without destroying the biological activity of the resultant molecule include A-chain residues 1 through 22 and 96 through 104. Particularly preferred truncated A-chain analogs consist of amino acids 1 through 95, 9 through 95, 23 through 95, 9 through 104, and 23 through 104, although it will be evident to those skilled in the art that other polypeptides may also be constructed while still providing a molecule having biological activity. Further, amino acids which may be deleted without destroying the biological activity of the resultant B-chain molecule include residues 1 through 28 and residues 102 through 109. Particularly preferred truncated B-chain analogs consist of amino acids 1 through 101, 15 through 101, 29 through 101, 15 through 109, and 29 through 109, although it will be evident to those skilled in the art that other polypeptides may also be constructed while still providing a molecule having biological activity.

In addition, a variety of amino acid substitutions are possible. Preferred amino acid substitutions include replacement of selected cysteine residues with another amino acid, e.g., serine, as well as the replacement of other amino acids, the substitution of which does not destroy the biological activity of the resultant molecule. While the dimerization of the proteins of the present invention involves disulfide bonding between the component chains, it has been found that not all of the cysteine residues participate in the formation of disulfide bonds or are necessary for biological activity. Cysteine residues at positions 43, 54 and 91 of the A-chain are essential for the formation of biologically active molecules. Cys 93 may also contribute to proper structure. The cysteine at position 10 may not be required for the formation of biologically active molecules. The remaining cysteines at positions 37, 46, and 47 are not required for the formation of active dimers. Therefore, proteins having amino acid substitutions at residues 10, 37, 46, 47 or 93 may also be suitable for use within the present invention, such as within a method for enhancing the wound-healing process in warm-blooded animals. Further, A-chain molecules containing more than one cysteine to serine mutation may also be biologically active. Preferred combinations include serine substitutions at positions 37 and 46 or at positions 37 and 47. Combinations of serines at positions 37 and 10 or 93 may also be suitable within the present invention.

Further, cysteine residues at positions 49, 60 and 97 of the B-chain are essential for the formation of active molecules. Cys 99 may also contribute to proper structure. The cysteine at position 16 may not be required for the formation of active dimers. The remaining cysteines at positions 43, 52 and 53 are not required for the formation of active molecules. Therefore, B-chain-like polypeptides having amino acid substitutions at residues 16, 49, 52, 53 or 99 may also be suitable for use within the present invention, such as within a method for enhancing the wound-healing process in warm-blooded animals. Further, B-chain molecules containing more than one cysteine to serine mutation may also be biologically active. Preferred combinations include serine substitutions at positions 43 and 52 or at positions 43 and 53. Combinations of serine substitutions at positions 43 and 16 or 99 may also be suitable within the present invention.

Other preferred amino acid substitutions include the replacement of a phenylalanine residue in the B-chain with a tyrosine residue. This substitution is useful, for instance, in facilitating the radioactive iodination of the B-chain as a laboratory reagent for use in binding and localization studies. The tyrosine residues are labelled with iodine under mild conditions which do not alter the biological activity of the protein. Preferred tyrosine for phenylalanine substitutions are at positions 23 and 37 of the B-chain. This was accomplished by oligonucleotide-directed mutagenesis following standard methodology. Oligonucleotide ZC1116(5'-AGATC-TCGTAAACTTCGG-3') was used to introduce the tyrosine substitution at position 23. Similar substitutions can be made for the other phenylalanine residues in the B-chain.

In addition to the amino acid substitutions described above, certain other amino acid substitutions are also possible, as long as the resultant polypeptide retains substantial homology to the A- or B-chain of PDGF. For example, a DNA sequence derived from the v-sis gene encodes a protein which, although homologous to the human B-chain, differs from the human amino acid sequence at four positions. Biologically active dimers may be made using the v-sis sequence or the authentic human sequence, which may be derived from a human cDNA or constructed by altering the v-sis sequence as described herein.

There are a variety of variants and derivatives which may be used within the present invention. For instance, amino acid substitutions may be made in either the A-chain or the B-chain which: (a) modify the three-dimensional structure of the particular chain without significantly affecting its biological activity; (b) modify the three-dimensional structure, resulting in an alteration of the biological activity; or (c) affect biological activity without significantly changing the three-dimensional structure. For example, amino acid number 98 in the B-chain may be changed from lysine to leucine, resulting in a monomer-sized molecule exhibiting biological activity. Alternatively, biologically active monomers may be obtained by changing cysteine residues involved in interchain disulfide bonds between the polypeptides of the dimer to an amino acid which will not form a disulfide bond. Molecules which are biologically active as monomers may permit greater therapeutic application. Monomer analogs can also be further manipulated without the requirement

for the formation of a dimer to obtain biological activity. This will facilitate structural analysis, leading to the definition of an active receptor binding site, thereby allowing the design of additional therapeutic analogs.

Further, deletion of one or more amino acids can also result in a modification of the structure of the resultant molecule without significantly altering its biological activity. This can lead to the development of a smaller active molecule which would have broader therapeutic utility. For example, as described herein, one can remove amino terminal amino acids not required for biological activity. Similarly, carboxy terminal amino acids may be removed, while retaining biological activity.

Further, mosaics of portions of the A- and B-chains or their derivatives may also be used within the present invention. The term "mosaic," as used within the present invention, includes contiguous portions of the A-chain and the B-chain sufficient to encode a molecule having biological activity as defined herein. The constituent portions of the mosaic can be chosen from wild-type A-chain or B-chain, as well as variants or derivatives of the A-chain or B-chain. The portions of the mosaic may range from 1 to approximately 75 amino acids in length, provided that the overall primary structural features of the A- and B-chains are maintained. The common structural features of the A- and B-chains are the relative positions of (a) the cysteine residues; (b) the regions of amino acid charge; and (c) regions of hydrophobic and hydrophilic character. In addition, it may be useful to maintain the blocks of sequence identity between the A- and B-chains.

As a further alternative, the sequences of these hybrids may be modified, while retaining biological activity. For example, one or more amino acid changes, such as a change at A-chain amino acid number 10 or in B-chain at amino acid 16 from a cysteine to a serine results in a molecule retaining biological activity.

Further, combinations of the A- and B-chains or their derivatives may also be used within the present invention. The term "combinations," as used within the present invention, includes heterodimers composed of two different polypeptides; e.g., the A-chain and the B-chain. The constituent polypeptides of the heterodimer can be chosen from wild-type A-chain or B-chain or portions thereof, as well as variants or derivatives of the A-chain or B-chain. The DNA sequences to be utilized in expressing these polypeptides may be isolated, synthesized or constructed using standard recombinant DNA techniques.

In order to produce A-B heterodimers in yeast, constructs expressing both the A-chain and the B-chain of PDGF are introduced into the same yeast cell. In this way both polypeptide chains transit the secretory pathway simultaneously and are able to assemble into heterodimers. A preferred method is to place the A-chain and B-chain expression constructs on a single plasmid. In this way the copy number of the two sequences remains equal. It is also possible to introduce into and maintain within the same yeast cell separate plasmids, one encoding A-chain and the other B-chain.

Within the present invention, it has been found that by utilizing the secretory pathway of eucaryotic cells to express proteins substantially homologous or substantially identical to the A-chain or B-chain of PDGF or portions thereof, biologically active PDGF analogs may be obtained. Expression and secretion of these gene products from a eucaryotic cell enable processing and assembly, which result in molecules with native and biologically active conformation.

The secretory pathways of eucaryotes are believed to be quite similar. In particular, mammalian cell and yeast cell secretory pathways are well characterized and are homologous. The presence of a secretory signal sequence on the expressed polypeptide is an important element in eucaryotes, due to its role in directing the primary translation product into the secretory pathway, thereby leading to proper processing and assembly. Provided that appropriate transcriptional promoter and secretory signal sequences are utilized, generally any eucaryote could express and secrete PDGF-analogs in a biologically active form.

An easily manipulable and well-characterized eucaryote is the yeast cell. For these reasons, yeast was chosen as a model example of an appropriate eucaryotic cell within the present invention. In accordance with the present invention, the yeast promoter is followed downstream by a DNA sequence which encodes a protein having substantially the same biological activity as PDGF. For example, DNA sequences encoding the 109 amino acids of the PDGF B-chain or the 104 amino acids of the A-chain were inserted into yeast extrachromosomal elements containing a yeast promoter capable of directing their expression. These extrachromosomal elements were transformed into yeast cells capable of expression and secretion of these biologically active PDGF analogs. In addition, variants and derivatives of the PDGF A- and B-chains, as well as the mosaic sequences, were also inserted into such a yeast extrachromosomal element.

The genes or sequences to be utilized in the present invention may be isolated using standard recombinant DNA techniques.

DNA sequences which encode a protein having substantially the same structure and/or biological activity as PDGF include the v-sis gene or derivatives of the v-sis gene, or portions thereof, or the human cDNAs for the A-chain or the B-chain of PDGF or portions thereof.

The human PDGF B-chain cDNA is isolated from a human cDNA library made from an appropriate source of messenger RNA, preferably by using the v-sis gene or a fragment thereof as a hybridization probe, or through use of oligonucleotide probes designed from the B-chain DNA sequence. A preferred source of mRNA is human umbilical vein endothelial cells. These cells can be cultured *in vitro* for short periods of time and are known to secrete PDGF into the culture medium (DiCorleto and Bowen-Pope, *PNAS* 80: 1919, 1983) and contain high levels of B-chain mRNA. Briefly, polyadenylated RNA was prepared from freshly cultured human umbilical vein endothelial cells and used to make double-stranded cDNA by conventional techniques. This cDNA was cloned in bacteriophage lambda gt11. The resulting cDNA library was screened with probes derived from the v-sis gene. A second such library was made and screened in a similar fashion. Clones identified in this manner were mapped by restriction enzyme analysis in order to establish their extent of overlap. The identity of these clones as encoding PDGF B-chain was verified by DNA sequencing.

The human A-chain cDNA may be isolated from a human cDNA library made from an appropriate source of messenger RNA by using the v-sis gene or a fragment thereof as a hybridization probe, or through use of oligonucleotide probes designed from the A-chain DNA or amino acid sequence (see, for example, Betsholtz et al., *Nature* 320: 695-699, 1986). Preferred sources of mRNA are human transformed cell lines, e.g., U2-OS and T-24. These cells can be cultured *in vitro* and are known to secrete a protein having PDGF-like activity (Heldin et al., *Nature* 319: 511-514, 1986). The identity of this cDNA as that encoding A-chain may be verified by DNA sequencing.

In addition, suitable DNA sequences may be constructed using synthetic oligonucleotides.

Once an appropriate DNA sequence encoding a protein exhibiting PDGF-like biological activity is identified, the sequence is ligated to an appropriate promoter and secretory signal fragment. Promoters which may be utilized in yeast include the yeast alpha-factor ( $MF_{\alpha}1$ ) promoter and the yeast triose phosphate isomerase (TPI1) promoter (Kawasaki, U.S. Patent No. 4,599,311). Promoters may also be obtained from other yeast genes, e.g., alcohol dehydrogenase 1 (ADH1), alcohol dehydrogenase 2 (ADH2). Appropriate promoters for other eucaryotic species may also be used and will be apparent to those skilled in the art. The constructions described herein were designed such that the PDGF-related gene products would be secreted from the host cell into the media. In yeast, this was accomplished through use of the prepro secretory signal sequence of the yeast mating pheromone alpha-factor (Kurjan and Herskowitz, *Cell* 30: 933, 1982; Julius et al., *Cell* 36: 309, 1984; and Brake et al., *PNAS* 81: 4642, 1984), although other secretion signals may be used. To ensure the efficient transcription termination and polyadenylation of mRNA, a yeast terminator sequence, such as the TPI1 terminator (Alber and Kawasaki, *J. Molec. Genet. Appl.* 1: 419, 1982), was added. Methods of ligation of DNA fragments have been amply described (Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory 1982) and are well within the skill of those of ordinary skill in the art to perform. After preparation of the expression unit constructions, the constructs are inserted into an appropriate expression vector.

It is preferable to use an expression vector which is stably maintained within the host cell in order to produce more biological activity per unit of culture. Suitable yeast expression vectors in this regard include the plasmids pCPOT and pMPOT2, which include the *Schizosaccharomyces pombe* gene encoding the glycolytic enzyme triose phosphate isomerase (POT1 gene). Inclusion of the POT1 gene ensures the stable maintenance of the plasmid in an appropriate host cell having a deletion in the TPI gene due to its ability to complement the host cell gene deletion. Other selection systems may also be used, such as the *leu2* selection system described by Beggs (*Nature* 275: 104-109, 1978).

After preparation of the DNA construct incorporating the promoter, the alpha-factor secretory signal sequences, the appropriate DNA sequence encoding a molecule having PDGF-like biological activity, and the TPI terminator in an appropriate vector, the construct is transformed into the yeast host with a TPI deletion. Procedures for transforming yeast are well known in the literature (see, for example, Beggs, *ibid.* and Hinnen et al., *Proc. Natl. Acad. Sci. U.S.A.* 75: 1929-1933, 1978).

The transformed yeast cells may be selected by growth on conventional complex medium containing glucose when the pCPOT or pMPOT2 vector is utilized. A conventional medium, such as YEPD (20 grams glucose, 20 grams Bacto-peptone, 10 grams yeast extract per liter), may be used. Once selected, transformants containing the appropriate expression constructions are grown to stationary phase on conventional complex media, the cells removed by centrifugation or filtration, and the medium concentrated. Noting that authentic human PDGF is a highly cationic and hydrophobic protein (Raines and Ross, *ibid.*; Antoniades, *ibid.*; Deuel et al., 1981, *ibid.*), it was expected that the yeast-expressed, PDGF-related products would possess similar characteristics, allowing the use of ion-exchange chromatography in their purification.

Using a variety of assays, it can be demonstrated that spent media from yeast cultures expressing the PDGF analogs possess biological activities substantially identical to authentic human PDGF.

Expression of biologically active PDGF analogs in eucaryotic cells other than yeast cells can be achieved by a person skilled in the art through use of appropriate expression/regulatory signals. Transcriptional promoters capable of directing the expression of these sequences are chosen for their ability to give efficient and/or regulated expression in the particular eucaryotic cell type. A variety of promoters are available, including viral (e.g., SV40 and adenovirus promoters) and cellular (e.g., metallothionein gene-karin, U.S. Patent No. 4,601,978) promoters. Signal sequences capable of directing the gene product into the cell's secretory pathway are chosen for their function in the appropriate cell type. Other useful regulatory signals, such as transcription termination signals, polyadenylation signals and transcriptional enhancer sequences, are also chosen for their function in the appropriate cell type, the selection of which would be apparent to an individual skilled in the art. Methods for transforming mammalian cells and expressing cloned DNA sequences are described by Kaufman and Sharp (*J. Mol. Biol.* 159: 601-621, 1982), Southern and Berg (*J. Mol. Appl. Genet.* 1: 327-341, 1982), and Neumann et al. (*EMBO J.* 1: 841-845, 1982).

According to the present invention, it is possible to produce recombinant PDGF-like molecules which are homodimers or heterodimers of substantially identical polypeptide chains. To produce heterodimers, two different expression units are introduced into the same cell and heterodimers are identified among the biologically active products. The expression units may be on different expression vectors with different selectable markers or, preferably, on a single expression vector. The second strategy offers the advantaged of providing equal copy numbers of the two expression units.

The techniques of cell culture have advanced considerably in the last several years as have the number and varieties of mammalian cells which will grow in culture. Central to these advances is a better understanding of the nutritional requirements (i.e., hormones and growth factors) of cultured cells (Barnes and Sato, *Cell* 22: 649, 1980). The types of cells able to grow in culture can be crudely classified in two groups: normal and transformed. So-called "normal" cells are generally not immortal in culture, they do not form tumors when injected into animals, and they retain a normal diploid karyotype. Normal cells may also retain much of their differentiated character in culture. Within the category of normal cells are those which will only grow for a limited number of generations in culture, termed "cell strains" or "primary cultures." Some normal cell lines, while not meeting all the criteria of transformation, may grow indefinitely in culture. Transformed cells are immortalized for growth in culture, typically have lost their differentiated phenotype, and have acquired karyotypic aberrations. They may also be independent of anchorage for growth and induce tumors when injected into the appropriate host animal. Cells in any of these categories which grow *in vitro* and possess PDGF receptors will be responsive to the PDGF analogs of this invention.

As noted above, the proteins described herein are suitable for use within therapeutic compositions for enhancing the wound-healing process in warm-blooded animals. The normal wound-healing process in warm-blooded animals proceeds by an orderly series of events involving the interaction of chemoattractants, growth factors, and a variety of specialized cell types. This process includes an ordered migration and, in some cases, the subsequent proliferation of a number of these specialized cell types into the wound space, and involves the complex interaction of a variety of biologically active factors. This process is discussed in detail in Hunt et al., eds., *Soft and Hard Tissue Repair; Biological and Clinical Aspects*, Praeger Publishers, New York, 1984, which is hereby incorporated by reference. Briefly, tissue injury results in the release of chemotactic factors which attract particular cell types, which then release additional and/or other chemoattractant or mitogenic factors. These factors, in turn, affect additional specialized cells, ultimately restoring the injured tissue. Further, there is evidence that the rate at which this process normally proceeds is limited by the levels of chemoattractants and growth factors at the wound site, and may be enhanced by the addition of these agents (Grotendorst et al., *J. Clin. Invest.* 76: 2323-2329, 1985, herein incorporated by reference).

The wound-healing process in the dermis begins with the formation of a clot from the blood which flows into the wound. This results in a cross-linked network of fibrin molecules binding the wound together. During this process, platelets adhere to the injured tissue, becoming activated, and release the contents of their alpha granules. The disruption of the dermal tissue, the blood coagulation reactions, and platelet activation all generate molecules which cause the migration of a series of new cells into the wound, thereby initiating the repair process.

Among the contents of the alpha granules released by the platelets is PDGF. In addition, other contents of the alpha granules and by-products of the coagulation reactions induce the appearance of macrophages. Macrophages are a second important source of PDGF in the wound. The deposition of PDGF at the site of an injury provides a chemotactic stimulus for fibroblasts to enter the wound space and a mitogenic stimulus for the fibroblasts to subsequently proliferate therein, thereby participating in the process of repair. An important role of the fibroblast is the regeneration of connective tissue at the wound site. The fibroblasts

proliferate in the wound and deposit collagen types I and II and other extracellular proteins to the connective tissue matrix. The presence of new fibroblasts and their protein products reconstitutes the dermal architecture such that it can be re-epithelialized and the wound thereby healed.

Similarly, the wound-healing process in relation to the repair of connective tissue also requires fibroblast infiltration and proliferation, leading to subsequent collagen deposition.

The proteins of the present invention have been shown to possess substantially the same biological activity as authentic PDGF. The basic biological activity of PDGF, particularly the induction of chemotaxis and mitogenesis in responsive cell types (including fibroblasts and smooth muscle cells), underlies many of the physiological roles of this protein, including its role in tissue repair.

Because the chemotactic and mitogenic properties of PDGF are central to its role in the wound-healing process, the biologically active proteins of the present invention will have similar therapeutic utility. These biologically active proteins are therefore expected to have clinical applicability in the treatment of wounds in which healing requires the migration and/or proliferation of fibroblasts. In addition, PDGF acts as a chemotactic and mitogenic agent for smooth muscle cells, the proliferation of which may contribute to the healing of certain wounds. Smooth muscle cells will be affected by PDGF in a manner similar to that described above for fibroblasts, thereby contributing to the healing process.

In individuals with normal healing capacity, exogenous proteins having the biological activity of PDGF accelerate the rate of appearance of fibroblasts in the wound and their subsequent proliferation. In addition, there are a large number of individuals who have substantially impaired wound healing capacity, and thereby lack the ability to provide to the wound site endogenous growth factors which are necessary for the process of wound healing. In these individuals, the addition of exogenous proteins having the biological activity of PDGF enables wound healing to proceed in a normal manner.

The proteins of the present invention are expected to accelerate the healing process in a broad spectrum of wound conditions. For purposes of the present invention, the terms "wound" or "wound condition" include any disruption of the dermal layer of the skin. Examples of disruptions to the dermal layer include chronic non-healing dermal ulcers (which can have a variety of causes), superficial wounds and lacerations, abrasions, surgical wounds, and some burns. In addition, wounds may also result in damage to connective tissue, the repair of which involves fibroblast proliferation and collagen deposition. The proteins of the present invention are useful in enhancing the healing process of all of these wounds, and will also be useful in the treatment of other wounds in which healing requires the migration and/or proliferation of fibroblasts. Furthermore, normal wound-healing may be retarded by a number of factors, including advanced age, diabetes, cancer, and treatment with anti-inflammatory drugs or anticoagulants, and the proteins described herein may be used to offset the delayed wound-healing effects of such treatments. Lawrence et al., (Ann. Surgery 203: 142-147, 1986) demonstrated that PDGF restored the wound-healing process to normal in diabetic rats. Knighton et al., (Ann. Surgery 204: 322-330, 1986) used a mixed growth factor preparation comprising PDGF on chronic non-healing dermal wounds of human patients and observed dramatic positive results. Their results indicate that some of the activity in their preparation is due to PDGF and that PDGF contributes to the rapid healing they see in humans as it does in animal experiments. PDGF acts synergistically with other components of the preparation.

For therapeutic use in the applications described herein, the proteins of the present invention are preferably administered topically in combination with a physiologically acceptable carrier or diluent. Further, it is preferable to use a substantially pure preparation of the protein, that is, one which is generally free of impurities or contaminants which would interfere with its therapeutic use. Particularly preferred are those preparations which are free of toxic, antigenic, inflammatory or other deleterious substances, and are greater than 80% pure. Typically, the proteins desired herein will be in a concentration of about 1 to 50  $\mu\text{g/ml}$  of total volume, although it will be apparent that concentrations in the range of 10  $\mu\text{g/ml}$  to 100  $\mu\text{g/ml}$  may be used. However, it should be noted that concentrations in excess of 50  $\mu\text{g/ml}$  may result in reduced therapeutic effectiveness. A therapeutically effective amount sufficient to accelerate the rate of appearance and increase the number of new fibroblasts in the wound space and to stimulate DNA synthesis in and collagen deposition by those fibroblasts, will typically be in the range of 1 to 5 milliliters of the preparation, depending upon the characteristics of the wound.

Therapeutic compositions according to the present invention comprise the proteins described herein in combination with suitable carriers, as well as adjuvants, diluents, or stabilizers. Suitable adjuvants include collagen or hyaluronic acid preparations, fibronectin, factor XIII, or other proteins or substances designed to stabilize or otherwise enhance the active therapeutic ingredient(s). Diluents include albumins, saline, sterile water, etc. Other stabilizers, antioxidants, or protease inhibitors may also be added. Alternatively, the proteins may be applied to wound dressings as aqueous solutions. The therapeutic compositions according to the present invention may be reapplied at one- to several-day intervals until healing is complete.

The therapeutic compositions of the present invention may also contain other pharmaceutically active ingredients, for example, heparin, which has been shown to accelerate the healing of thermal burns. Other growth factors, such as TGF- $\alpha$ , TGF- $\beta$ , EGF, FGF, platelet factor 4, insulin or somatomedins (see Grotendorst et al., 1985) and angiogenesis factor, may also work synergistically with the PDGF analogs described herein. Antibiotics may also be included to keep the wound free of infection.

To summarize the examples which follow, EXAMPLE I demonstrates the construction of a v-sis subclone of pSSV-11 in the *E. coli* replicating plasmid pUC13, subsequently designated pVSIS/Pst. EXAMPLE II demonstrates the construction of the plasmid pVS $\alpha$ , which includes the ligation of v-sis to the MF $\alpha$ 1 promoter and secretory signal sequence. EXAMPLE III demonstrates the oligonucleotide-directed deletion mutagenesis of the first 195 base pairs of the v-sis gene using a technique which employs single stranded bacteriophage M13 in order to eliminate the first sixty-six amino acids of the v-sis gene product, p28<sup>sis</sup>, which are not homologous to the B-chain of PDGF. A resulting phage with the correct deletion was designated m11vs2 $\alpha$ . EXAMPLE IV demonstrates the construction of the expression vector pVSBm. EXAMPLE V demonstrates the transformation of yeast host cells. EXAMPLE VI demonstrates the construction of pSB1. EXAMPLE VII demonstrates the construction of variants and derivatives of the B-chain. EXAMPLE VIII demonstrates the construction of variants and derivatives of the A-chain. EXAMPLE IX demonstrates the construction of yeast expression vectors for A- and B-chain variants and derivatives. EXAMPLE X demonstrates a method for producing an A-B heterodimer in yeast. EXAMPLE XI demonstrates the concentration of the spent yeast growth media from transformed cultures and subsequent analysis for PDGF-like material. Clear evidence is presented that these yeast media containing the PDGF analogs described herein possess substantially the same biological activity as authentic human PDGF. EXAMPLE XII demonstrates methods for optimizing protein expression.

The following examples are offered by way of illustration, and not by way of limitation.

#### EXAMPLE I

##### Subcloning of v-sis from pSSV-11

The SSV retroviral genome was cloned from SSV-11 nonproductively infected normal rat kidney (NRK) cells which had SSV integrated into their genome (Devare et al., 1982, *ibid.*). The SSV DNA was isolated as a 5.8 kilobase (kb) Eco RI fragment and subsequently inserted into the plasmid pBR322, resulting in the clone pSSV-11. This clone was obtained from S. Aaronson (National Institutes of Health, Bethesda, MD).

Figure 1A is a schematic restriction map of the 5.8 kilobase proviral genome of SSV. Only the restriction sites relevant to the present invention are indicated. The open box designates the p28<sup>sis</sup> coding portion of the v-sis gene.

Figure 1B depicts the nucleotide sequence of the v-sis gene and some flanking SSV sequences. The v-sis gene is inserted 19 nucleotides 3' of the putative ATG initiation codon of the envelope (env) gene of SSV (Devare et al., 1982, *ibid.*). It is believed that transcription and translation of v-sis sequences are directed by SSV sequences resulting in an env-sis fusion protein. The nucleotide sequence shown in Figure 1B is corrected from that published by Devare et al. in 1982 (*ibid.*). The corrections include those made by Devare et al. in 1983 (*ibid.*) and by the inventors herein. The original numbering scheme of Devare et al. (1982, *ibid.*) is retained here for ease of reference. The numbers assigned to the restriction sites in Figure 1A are from Figure 1B.

A subclone of pSSV-11 (Figure 2) containing a portion of the v-sis gene was constructed in the *E. coli* replicating plasmid pUC13 (Vieira and Messing, *Gene*, 19: 259, 1982; and Messing, *Meth. in Enzymology* 101: 20, 1983). five micrograms ( $\mu$ g) of pSSV-11 was digested with the restriction endonuclease Pst I and the 1.2 kb fragment containing sequences numbered 454-1679 (Figure 1) was purified by agarose gel electrophoresis (0.9%) and extracted from the gel with cetyltrimethylammonium bromide (CTAB) plus butanol (Langridge et al., *ibid.*). Two  $\mu$ g of pUC13 was also digested with Pst I, phenol/chloroform (CHCl<sub>3</sub>) extracted and ethanol (EtOH) precipitated. Forty ng of the 1.2 kb v-sis fragment and 50 ng of Pst I-cut pUC13 were ligated overnight at room temperature with 40 units (u) of T<sub>4</sub> DNA ligase. The ligation mixture was used to transform *E. coli* K-12 strain JM83 (Messing, *Recombinant DNA Technical Bulletin*, NIH Publication No. 79-009, 2, No. 2, 43-48, 1979) in the presence of 5-bromo, 4-chloro, 3-indolyl- $\beta$ -D-galactoside (X-gal) and isopropyl  $\beta$ -D-thiogalactoside (IPTG). Plasmid DNA prepared from ampicillin-resistant white colonies was digested with Pst I to verify the presence of the insert and the resulting plasmid was designated pVSIS/Pst.

## EXAMPLE II

Construction of the Plasmid pVS $\alpha$ 5 A. Preparation of v-sis for Fusion to MF $\alpha$ 1.

Six hundred  $\mu$ g of plasmid pSSV-11 (Figure 2) was digested with restriction endonucleases Bam HI and Pvu II in 200 microliters ( $\mu$ l) of 50 mM NaCl, 10 mM MgCl<sub>2</sub>, 10 mM Tris pH 7.5 (medium salt buffer), and 100  $\mu$ g/ml bovine serum albumin (BSA), overnight at 37 °C. The digestion products were electrophoresed  
 10 through a 1.1% agarose gel and the 1100 base pair (bp) Bam HI--Pvu II fragment (Figure 2) cut out, extracted and EtOH precipitated. The DNA pellet was dissolved in 75  $\mu$ l Hph I buffer to which was added 20  $\mu$ l of 1 mg/ml BSA and 5  $\mu$ l Hph I. After overnight digestion at 37 °C, the mixture was electrophoresed through a 1.25% agarose gel and the 396 bp Hph I--Pvu II fragment isolated from the gel and EtOH precipitated. The DNA pellet was dissolved in 30  $\mu$ l of Klenow buffer (6mM Tris pH 7.5, 6 mM MgCl<sub>2</sub>, 60  
 15 mM NaCl) and the 3' overhanging nucleotide at the Hph I cleavage site removed by treatment with 5 u of Klenow polymerase for 5 minutes at 37 °C. One  $\mu$ l of a mixture containing all four deoxyribonucleotides each at 1 mM was added and the reaction mixture incubated an additional 10 minutes. After phenol/CHCl<sub>3</sub>/ether (Et<sub>2</sub>O) extraction and EtOH precipitation, the DNA pellet was dissolved in 30  $\mu$ l of medium salt buffer and digested with 5 u of Bgl II for three hours at 37 °C. The DNA was electrophoresed  
 20 through a 1.25% agarose gel and the 269 bp Hph I--Bgl II fragment extracted and EtOH precipitated. The Hph I cleavage terminus of this Klenow blunted fragment begins with the tri-nucleotide sequence

5' ATG..... (Figure 2).  
 3' TAC.....

25

B. MF $\alpha$ 1 Promoter and Secretory Leader Fragment.

Plasmid p192 (Figure 3) comprises a portion of the gene for the yeast mating pheromone  $\alpha$ -factor (MF $\alpha$ 1 gene) cloned in the bacterial plasmid pUC13 (Vieira and Messing, *ibid.*; and Messing, *Meth. in Enzymology* 101: 20, 1983). Cloning of the MF $\alpha$ 1 gene from a genomic library has been described by Kurjan and Herskowitz (*ibid.*). The gene was isolated in this laboratory in a similar manner, using as starting material a yeast genomic library of partial Sau 3A fragments cloned into the Bam HI site of Yep13 (Nasmyth  
 35 and Tatchell, *Cell* 19: 753, 1980). From this library, a plasmid was isolated which expressed  $\alpha$ -factor in a diploid strain of yeast homozygous for the *mat $\alpha$ 2-34* mutation (Manney et al., *J. Cell Biol* 96: 1592, 1983). The clone contained an insert overlapping with the MF $\alpha$ 1 gene characterized by Kurjan and Herskowitz (*ibid.*). This plasmid, known as pZA2 (Figure 3), was cut with Eco RI and the 1700 bp fragment comprising the MF $\alpha$ 1 gene was purified. This fragment was then subcloned into the Eco RI site of pUC13 to produce  
 40 the plasmid p192.

Fifteen  $\mu$ g of plasmid p192 was digested in 30  $\mu$ l of medium salt buffer with 20 units of Hind III overnight at 37 °C. The reaction mixture was diluted to 60  $\mu$ l with Klenow buffer and the four deoxyribonucleotides added to a final concentration of 50  $\mu$ M each. Ten units of Klenow polymerase were added to the ice-cold mixture and incubation allowed to proceed 12 minutes at 15 °C. Following  
 45 phenol/CHCl<sub>3</sub>/Et<sub>2</sub>O extraction, the aqueous phase was concentrated by lyophilization to a volume of 10  $\mu$ l and digested with 20 units of Eco RI for 70 minutes at 37 °C. The products were electrophoresed through a 0.9% agarose gel and the 1.2 kb Eco RI--Hind III (blunted) MF $\alpha$ 1 fragment extracted and EtOH precipitated. This DNA fragment contains the transcriptional promoter and secretory signal sequences of MF $\alpha$ 1.

## 50 C. Preparation of v-sis 3' Sequences and Cloning Vector pUC12; Fragment Ligation.

Twenty  $\mu$ g of plasmid pVSIS/Pst was digested with Bgl II and Xba I in 40  $\mu$ l of medium salt buffer. Subsequent electrophoresis through 1% agarose, extraction of the DNA and EtOH precipitation provided the purified v-sis 756 bp Bgl II--Xba I fragment (Figure 2). *E. coli* replicating plasmid pUC12 (5  $\mu$ g) was  
 55 digested with Eco RI and Xba I and gel-purified as above (Figure 2).

Referring to Figure 2, equimolar amounts of the four DNA fragments described above, adjusted to 10 ng of the 296 bp Hph I--Bgl II v-sis fragment, were mixed in 15  $\mu$ l of ligase buffer (6 mM Tris pH 7.6, 6.6 mM MgCl<sub>2</sub>, 0.4 mM ATP, 2 mM spermidine, 20 mM DTT, and 100  $\mu$ g/ml BSA) and ligated with 40 units of

T<sub>4</sub> DNA ligase overnight at 14 °C. The reaction mixture was brought to room temperature, an additional 150 units of T<sub>4</sub> ligase added, and incubated 10 more hours. Seven  $\mu$ l of the ligation mix was used to transform *E. coli* K-12 RR1 (ATCC #31343; Bolivar et al., *Gene* 2: 95, 1977), and ampicillin-resistant transformants selected. Plasmid DNA was prepared from twelve such bacterial colonies and digested with Xba I. Two clones gave a 2.2 kb band predicted by the proper fragment, alignment (Figure 2). Further analysis of these by Bgl II-Xba I restriction mapping gave expected bands of approximately 1.5 kb from the MF $\alpha$ 1/v-sis fusion and 760 bp for the Bgl II-Xba I v-sis fragment. DNA sequence analysis verified the desired nucleotide sequence at the MF $\alpha$ 1/v-sis junction. The resultant plasmid was designated pVS $\alpha$ .

#### EXAMPLE III

##### Construction of m11VS2 $\alpha$

Homology between the v-sis protein p28<sup>sis</sup> and PDGF begins at amino acid 67 of p28<sup>sis</sup>, a serine residue corresponding to the NH<sub>2</sub> terminal residue of the PDGF B-chain (Johnsson, *ibid.*)

Proteolytic processing of the MF $\alpha$ 1 primary translation product occurs at the Lys-Arg cleavage signal 85 amino acids from the initiator methionine (Kurjan and Herskowitz, *ibid.*). A v-sis derivative was constructed in which the first 66 codons of p28<sup>sis</sup> were removed such that serine residue 67 of v-sis immediately follows the MF $\alpha$ 1 Lys-Arg processing signal.

Referring to Figure 4, approximately 40 ng of the gel purified 2.2 kb Xba I fragment of pVS $\alpha$  was ligated with 120 ng of Xba I digested, alkaline phosphatase-treated M13mp11 DNA (Messing, *Meth. in Enzymology*, *ibid.*). The ligation mixture was used to transform *E. coli* K-12 strain JM101 (ATCC 33876) in the presence of X-gal and IPTG. Isolated white plaques were picked and used to infect 3 ml cultures of log phase growth JM101 cells. Replicative Form (RF) DNA was prepared and clones identified which carried the insert fragment in the same orientation as the positive (+) strand form of the single-stranded mature phage. Single-stranded phage DNA was prepared from one such clone and designated m11VS $\alpha$ .

To precisely remove codons 1-66 of v-sis, oligonucleotide-directed mutagenesis was performed essentially according to the two-primer method of Zoller et al. (*Manual for Advanced Techniques in Molecular Cloning Course*, Cold Spring Harbor Laboratory, 1983). Oligonucleotide ZC 130 3' AGAAACC-TATTTTCCTCGGACCCA 5' was synthesized on an Applied Biosystems 380-A DNA synthesizer. Fifty pmoles of ZC 130 was kinased in 10  $\mu$ l of kinase buffer (BRL) with 4 units of T<sub>4</sub> polynucleotide kinase for 45 minutes at 37 °C. The enzyme was inactivated by heating at 65 °C for 10 minutes.

One-half pmole of m11VS $\alpha$  was annealed with 1 pmole of kinased ZC130 and 1.5 pmoles of universal sequencing primer (BRL) using conditions described (Zoller et al., *ibid.*), except that the annealing mixture was first heated to 65 °C for 10 minutes, shifted to 37 °C for 10 minutes, and then quickly chilled on ice. The annealed mixture was then treated with Klenow polymerase as described by Zoller et al. (*ibid.*) to create circular duplex DNA. Portions of the elongation mixture were used to transform *E. coli* K12 JM101 cells. The resulting phage plaques were screened for the proper deletion by transfer onto nitrocellulose filters and subsequent hybridization with <sup>32</sup>P-phosphorylated ZC130 at 65 °C. Correctly juxtaposed sequences formed stable duplexes with the radioactive probe at the stringent hybridization temperature employed. Approximately 1% of the transformants screened gave positive signals by autoradiography. Ten clones were plaque-purified and RF DNA was prepared for restriction enzyme analysis. Five isolates showed the expected decrease in size of 195 bp to the 1450 bp Hind III-Bgl II fragment (Figure 4). DNA sequence analysis of two isolates confirmed the correct fusion junction had been made, thus maintaining the proper translational reading frame. One of these phage was designated m11VS2 $\alpha$ .

#### EXAMPLE IV

##### Construction of pVSBm

##### A. Construction of Plasmids YEpVS $\alpha$ and YEpVS2 $\alpha$ .

Yeast-replicating vector YEp13 (Broach et al., *Gene* 8: 121, 1979) was used as an expression vehicle for v-sis-derived constructions described in Examples II and III. YEp13 is a multicopy extrachromosomal plasmid containing a 2 micron replication origin and the yeast LEU2 gene. This allows for selection of the plasmid in yeast strains possessing a defective chromosomal LEU2 gene when grown on synthetic medium lacking leucine. Addition of yeast terminator sequences to foreign genes expressed in yeast ensures efficient transcription termination and polyadenylation of mRNA. The v-sis expression units VS $\alpha$  and VS2 $\alpha$

were placed adjacent to the TPI terminator fragment which was previously cloned into YEp13 (below).

Plasmid p270 (see Figure 5) contains the transcription terminator region of the yeast triose phosphate isomerase (TPI) gene. It was constructed in the following manner. The yeast TPI terminator fragment was obtained from plasmid pFG1 (Albert and Kawasaki, *ibid.*). It encompasses the region from the penultimate amino acid codon of the TPI gene to the Eco RI site approximately 700 base pairs downstream. A Bam HI site was substituted for this unique Eco RI site of pFG1 by first cutting the plasmid with Eco RI, then blunting the ends with DNA polymerase I (Klenow fragment), adding synthetic Bam HI linkers (CGGATCCA), and re-ligating to produce plasmid p136. The TPI terminator was then excised from p136 as a Xba I--Bam HI fragment. This fragment was ligated into YEp13 (Broach et al., *ibid.*), which had been linearized with Xba I and Bam HI. The resulting plasmid is known as p213. The Hind III site was then removed from the TPI terminator region of p213 by digesting the plasmid with Hind III, blunting the resultant termini with DNA polymerase I (Klenow fragment), and recircularizing the linear molecule using T<sub>4</sub> DNA ligase. The resulting plasmid is p270.

Alternatively, p270 may be constructed by digesting plasmid pM220 (see below) with Xba I and Bam HI, purifying the TPI terminator fragment (~700 bp) and inserting this fragment into Xba I and Bam HI digested YEp13.

Referring to Figure 6, plasmid p270 DNA was digested with Xba I and treated with calf alkaline phosphatase to prevent religation of the cohesive vector ends. V-sis expression units VS $\alpha$  and VS2 $\alpha$  were prepared by Xba I digestion and agarose gel purification of pVS $\alpha$  and m11vs2 $\alpha$ , respectively. Each of the isolated fragments was ligated with an approximately equimolar amount of phosphatased p270 vector in the presence of 40 units of T<sub>4</sub> DNA ligase and the ligation mixtures transformed into *E. coli* K-12 RR1. Plasmid DNA was prepared from ampicillin-resistant colonies and restriction enzyme analysis performed in order to identify clones which possessed the TPI terminator adjacent to 3' v-sis sequences. Presence of 3.3 kb or 3.1 kb Bgl II fragments after gel electrophoresis indicated the correct orientation of YEpVS $\alpha$  and YEpVS2 $\alpha$ , respectively.

#### B. Construction of the Plasmid pVSB.

Because the product encoded by pVS2 $\alpha$  is larger than authentic human PDGF B-chain and because a smaller product might result in higher expression levels in a transformed yeast host cell, a vector was constructed comprising the v-sis sequence of pVS2 $\alpha$  truncated at the 3' end. The polypeptide encoded by this sequence comprises amino acids 67 to 175 of p28<sup>sis</sup> and is homologous to the B-chain of PDGF.

An expression vector containing this "B-chain" sequence was constructed by combining elements of the pVS2 $\alpha$  expression unit with a partial v-sis gene and a synthetic double-stranded DNA fragment encoding amino acids 158 to 175 of p28<sup>sis</sup>. This synthetic fragment was designed to substitute preferred yeast codons for many of the 13 v-sis codons it replaces, and to supply a stop codon at the end of the coding sequence. The construction of this vector is illustrated in Figures 7 and 8.

Plasmid YEpVS2 $\alpha$  was digested with Pst I and Bam HI; and the 1.8 kb fragment, comprising the partial MF $\alpha$ 1, v-sis, and TPI terminator sequences, was purified by agarose gel electrophoresis. Plasmid pIC19R (Marsh et al., *Gene* 32: 481-486, 1984), comprising the polylinker shown in Chart 1 inserted into the Hind III site of pUC19 (Norrande et al., *Gene* 26: 101-106, 1983), was digested with Pst I and Bam HI, and the vector fragment was gel-purified and joined to the 1.8 kb fragment from pVS2 $\alpha$  to produce plasmid pVS2 $\alpha$ T.

#### CHART 1

GAATTCATCGATATCTAGATCTCGAGCTCGCGAAAGCTT

Eco RI   Eco RV   Bgl II   Sac I   Hind III

Cla I   Xba I   Xho I   Nru I

The *S. cerevisiae* TPI promoter was used to control expression of VS2 $\alpha$  sequences in a yeast expression vector. Plasmid pM220 contains the TPI promoter fused to the MF $\alpha$ 1 signal sequence. *E. coli* RRI transformed with pM220 has been deposited with American Type Culture Collection under accession number 39853.

Plasmid pM220 was digested with Bgl II and Pst I (Figure 7), and the ca. 1 kb fragment comprising the TPI promoter and the 5' portion of the MF $\alpha$ 1 sequence was isolated and cloned in Bgl II + Pst I-digested pIC19R. The resultant plasmid was digested with Cla I and Pst I, and the TPI promoter--MF $\alpha$ 1 fragment was gel-purified. Plasmid pVS2 $\alpha$ T was then cut with Cla I and Pst I and joined to the TPI promoter--MF $\alpha$ 1 fragment. The correct construct was identified by the presence of a 2.6 kb Cla I--Bam HI fragment and was designated pTVS2 $\alpha$ T.

Ten  $\mu$ g of plasmid pVS $\alpha$  was digested with Xma I and Sph I (Figure 8) to completion. The resulting ca. 4.9 kb vector fragment, which also comprises most of the v-sis sequence, was purified by agarose gel electrophoresis, extraction of the DNA and EtOH precipitation.

In order to supply a new 3' terminus for the v-sis sequence, a double-stranded DNA fragment was constructed from oligonucleotides synthesized on an Applied Biosystems Model 380-A DNA synthesizer. 0.7 pmole of oligonucleotide ZC299 (Table 1) was heated with an equimolar amount of oligonucleotide ZC300 in a volume of 10  $\mu$ l containing 40 mM NaCl for 5 minutes at 65 °C.

TABLE 1

ZC299: 5'TAAG TGT GAA ATC GTT GCC GCG GCT AGA GCT GTT ACC  
TAA TCT AGA<sup>3'</sup>

ZC300: 3'GTACA TTC ACA CTT TAG CAA CGG CGC CGA TCT CGA CAA  
TGG ATT AGA TCT GGCC<sup>5'</sup>

The mixture was then incubated at 37 °C for 5 minutes and allowed to cool to room temperature. 0.2 pmole of the purified 4.9 kb vector fragment was added, the mixture ligated for 18 hours at 12 °C and used to transform *E. coli* HB101 (ATCC 33694) to ampicillin resistance. DNA was prepared from ampicillin-resistant colonies and digested with Bgl II and Xba I. After electrophoresis through agarose, the desired clone (known as pVS $\alpha$ B) was identified by loss of a ca. 750 bp Bgl II--Xba I fragment and appearance of two smaller fragments of approximately 500 and 260 bp.

Approximately 8  $\mu$ g of plasmid pTVS2 $\alpha$ T (Figure 8) were digested to completion with Xba I in a volume of 10  $\mu$ l. The volume was increased to 40  $\mu$ l with Bgl II buffer, and 6 units of Bgl II were added and the mixture was incubated at 37 °C. Ten  $\mu$ l aliquots were removed to a stop buffer containing 50 mM EDTA at 15 and 30 minutes, and the remaining 20  $\mu$ l stopped at 45 minutes. The resulting mixtures were separated by electrophoresis through 0.7% agarose. The ca. 4.6 kb Bgl II--Xba I vector fragment was cut out, extracted from the gel, and EtOH precipitated. Plasmid pVS $\alpha$ B was digested with Bgl II and Xba I, and the ca. 260 bp fragment containing the synthetic 3' terminus and stop codon was isolated by electrophoresis through agarose, subsequent extraction from the gel, and EtOH precipitation.

The 4.6 kb Bgl II--Xba I vector fragment from pTVS2 $\alpha$ T and the 260 bp Bgl II--Xba I fragment from pVS $\alpha$ B were ligated in the presence of T<sub>4</sub> DNA ligase for 7 hours at room temperature. The reaction mixture was used to transform *E. coli* HB101 to ampicillin resistance. DNA was prepared from transformants and the presence of the desired insert was confirmed by screening for a 550 bp Pst I--Xba I band on an agarose gel. A plasmid having the correct configuration was designated pVSB.

There are several alternative approaches which can be used to construct plasmid pVSB. The essential elements of pVSB include: the TPI promoter/alpha-factor fusion, which can be obtained from plasmid pM220, the B-chain coding sequence (base 551 through 877 of Figure 1B) of the v-sis gene, which is widely available, and the TPI terminator, which can be obtained from plasmid p270. Someone skilled in the art could develop several strategies to arrive at pVSB using these elements.

#### C. Construction of pMPOT2.

In order to achieve maximal protein production from a yeast culture, it is desirable to use expression vehicles which are very stably maintained in the host cell. Plasmid pCPOT is such a preferred expression vehicle.

*E. coli* HB101 transformed with pCPOT has been deposited with American Type Culture Collection under accession number 39685. Plasmid pCPOT comprises the 2 micron circle genome (Hartley and Donelson, *Nature* 286: 860, 1980), *E. coli* plasmid pBR322 replication and selection sequences, and the *Schizosaccharomyces pombe* DNA sequences encoding the glycolytic enzyme triose phosphate isomerase (POT1). Presence of the POT1 gene in pCPOT ensures stable maintenance of the plasmid in the appropriate host background during growth on nonselective medium utilizing glucose as a carbon source.

For expression of the *v-sis* derivatives in yeast, a stable expression vector comprising the REP1, REP2, REP3 and ori sequences from yeast 2 micron DNA and the *Schizosaccharomyces pombe* triose phosphate isomerase (POT1) gene was constructed. The POT1 gene provides for plasmid maintenance in a transformed yeast host grown in complex media if such host is defective for triose phosphate isomerase.

The POT1 gene was obtained from the plasmid pFATPOT. *S. cerevisiae* strain E18 transformed with pFATPOT has been deposited with ATCC under accession number 20699. The plasmid may be purified from the host cells by conventional techniques. The POT1 sequence was removed from pFATPOT by digestion of the plasmid with Sal I and Bam HI. This ~1600 bp fragment was then ligated to pIC19R, which had first been linearized by digestion with Sal I and Bam HI. The Bam HI, Pst I and Sal I sites in the resultant plasmid were destroyed in two steps to produce plasmid pICPOT\*. The Pst I and Sal I sites were removed by cutting with Pst I and Sal I; the ends were blunted by digesting the Pst I 3' overhang with DNA polymerase I (Klenow fragment) and filling in the Sal I 5' overhang with Klenow fragment. The blunt ends were then ligated. The Bam HI site was then removed by cutting the plasmid with Bam HI, filling in the ends with DNA polymerase I (Klenow fragment) and re-ligating the blunt ends.

The 2u sequences were obtained from the plasmids YEp13 (Broach et al., *Gene* 8: 121-133, 1979) and Cl/I. Cl/I was constructed from pJDB248 (Beggs, *Nature* 275: 104-109, 1978) by removal of the pMB9 sequences by partial digestion with Eco RI and replacement by Eco RI-cut pBR322. The REP3 and ori sequences were removed from YEp13 by digestion with Pst I and Xba I and gel purification. REP2 was obtained from Cl/I by digestion with Xba I and Sph I and gel purification. The two fragments were then joined to pUC18 (Norranders et al., *Gene* 26: 101-106, 1983) which had been linearized with Pst I and Sph I to produce plasmid pUCREP2,3. REP1 was obtained from Cl/I by digestion with Eco RI and Xba I and gel purification of the 1704 bp fragment. The Eco RI-Xba I fragment was cloned into pUC13 which had been linearized with Eco RI and Xba I. The resultant plasmid was designated pUC13 + REP1. The pUC13 + REP1 plasmid was cut with Hind II and ligated in the presence of Eco RI linkers (obtained from Bethesda Research Laboratories). The REP1 gene was then removed as an Eco RI fragment of approximately 1720 bp. This Eco RI fragment was cloned into pIC7 (Marsh et al., *ibid.*), which had been linearized with Eco RI and Xba I. The resultant plasmid was designated pICREP1#9.

To construct the final expression vector pMPOT2 (Figure 8), pICPOT\* was linearized by a partial Hind III digestion and complete Sst I digestion. Plasmid pUCREP2,3 was cut with Hind III and Sst I, and the fragment comprising REP2, REP3 and ori sequences was gel-purified and joined to the linearized pICPOT\*. The resultant plasmid, comprising REP2, REP3, ori, POT1 and amp<sup>r</sup> sequences, was designated pMPOT1. REP1 was then removed from pICREP1 as a Bgl II-Nar I fragment and was ligated to pMPOT1, which had been cleaved with Bgl II and Nar I. The product of this ligation was designated pMPOT2 (deposited with ATCC, accession number 20744). Plasmid pMPOT2 was digested with Cla I and Bam HI, and the vector fragment was purified as above.

#### D. Insertion of VSB expression unit into pMPOT2.

Plasmid pVSB was digested with Cla I and Bam HI, and the 2.2 kb fragment containing the "B-chain" expression unit purified by agarose gel electrophoresis and EtOH precipitation. Plasmid pMPOT2 was also digested with Cla I and Bam HI. The fragments were ligated overnight at room temperature in the presence of T<sub>4</sub> DNA ligase and the reaction mixture used to transform *E. coli* HB101 to ampicillin resistance. DNA was prepared from transformants and the presence of the insert verified by digestion with Cla I and Bam HI and agarose gel electrophoresis. The resulting expression vector was designated pVSBm (Figure 8).

#### EXAMPLE V

##### Yeast Transformation

Plasmids pVSBm and pMPOT2 were used to transform *S. cerevisiae* strain E18 #9 by conventional methods. Strain E18 #9 is a diploid produced by crossing strains E11-3c (ATCC No. 20727) ( $\Delta tpi::LEU2 pep4 leu2 MAT\alpha$ ) and  $\Delta tpi29$  ( $\Delta tpi::LEU2 pep4 leu2 his MATa$ ).  $\Delta tpi29$  is produced by disrupting the triose

phosphate isomerase gene of strain E2-7b (ATCC No. 20689), essentially as described by Rothstein (Meth. in Enzymology 101: 202-210, 1983).

#### EXAMPLE VI

5

#### Construction of pSB1

In order to begin replacing B-chain coding sequence with A-chain sequence in the pVSB vector, a convenient Sst I restriction endonuclease site was created close to the  $\alpha$ -factor prepro-B-chain boundary (Figure 8). This was accomplished by oligonucleotide-directed mutagenesis (Zoller and Smith, DNA 3: 479-488, 1984) on a single-stranded pVSB template using established techniques. The mutagenic oligonucleotide used is termed ZC506 and can be seen in Table 2.

15

**TABLE 2**

|    |       |                                                  |
|----|-------|--------------------------------------------------|
|    | ZC505 | GAACCCAGGCTTGCAGCTGGCAAAGATACCCC                 |
|    | ZC506 | GGCTCCTTTTGAGCTCAGATACCCCT                       |
| 20 | ZC545 | GATCTCGTAGATAACGGTACGCGTCTTACAAACAGCTCTCTTGAGCT  |
|    | ZC546 | CAAGAGAGCTGTTTGTAAGACGCGTACCGTTATCTACGA          |
|    | ZC547 | CAAGAGATCTATCGAAGAAGCGGTACCAGCCGTTTGTAAGACGCGTGA |

25

30

35

40

45

50

55

ZC548 GATCTCACGCGTCTTACAAACGGCTGGTACCGCTTCTTCGATAGATCT  
 CTTGAGCT  
 5 ZC671 CGCGTCTTAGAAACAGCTG  
 ZC672 GTACCAGCTGTTTCTAAGA  
 ZC675 CAAGTGTGAAACCGTTGCTGCTGCTAGACCAGTTACCTAAT  
 10 ZC676 CTAGATTAGGTAACCTGGTCTAGCAGCAGCAACGGTTTCACACTTGCATG  
 ZC685 CAAGAGATCCTTGGGTCTTTGACCATCGCTGAA  
 ZC686 AGCTGGTTCAGCGATGGTCAAAGAACCCAAGGATCTCTTGAGCT  
 ZC687 CCAGCTATGATCGCTGAATGTAAGACCAGAACCGAAGTTTTCGA  
 15 ZC688 GATCTCGAAAACCTTCGGTCTCTGGTCTTACATTCAGCGATCAT  
 ZC692 GATCCCAAGATCCCAAGTTGACCCAACCTCTGCCAACTTC  
 ZC693 TTGGCAGAGGTTGGGTCAACTTGGGATCTTGG  
 20 ZC746 TTGATTTGGCCACCATGTGTTGAAGTTAAGAGATGTACTGGGTGT  
 ZC747 CAGTACATCTCTTAACCTCAACACATGGTGGCCAAATCAAGAAG  
 ZC748 TGTCAAACCTCGAGTGTTAAGTGTCAACCATCCAGAGT  
 25 ZC749 GATGGTTGACACTTAACACTCGAGGTTTGACAACACC  
 ZC750 TCACCACAGATCCGTTAAGGTTGCCAAGGTTGAATACGTTAGAAAGAA  
 GCCAA  
 30 ZC751 AGCTTTGGCTTCTTTCTAACGTATTCAACCTTGGCAACCTTAACGGAT  
 CTGTGGTGAACCTCTG  
 ZC752 AGCTTAAGGAAGTTCAAGTTAGATTGGAAGAACACTTGGAAATGTGCAT  
 GCGCTACCACCTCTTTGAACCCAGACTACAGAGAATAAT  
 35 ZC753 CTAGATTATTCTCTGTAGTCTGGGTTCAAAGAGGTGGTAGCGCATGCA  
 CATTCCAAGTGTTCTTCCAATCTAACTTGAACCTTCCTTA  
 ZC ABA-1 CGCTTGTGCTACCACCTCTTTGAACCCAGACTACAGAGAATAAT  
 40 ZC ABA-2 CTAGATTATTCTCTGTAGTCTGGGTTCAAAGAGGTGGTAGCACAAGCG  
 CATG

A Pst I-Xba I fragment of pVSB (Figure 8) was subcloned into the M13 phage vector mp19. Single-  
 45 stranded template DNA was prepared from *E. coli* JM107 cultures infected with this recombinant phage and  
 used in the following mutagenesis reaction. Five  $\mu$ l of M13 template DNA (0.5 picomole) were combined  
 with 2 ml Of oligonucleotide ZC506 (1.8 pmole) plus 2.5  $\mu$ l of water and 1.5  $\mu$ l of 10X annealing buffer A  
 (0.2 M Tris-HCl, 0.0 M MgCl<sub>2</sub>, 0.01 M DTT pH 7.5; Zoller and Smith, *DNA* 3: 479-488, 1984). This mixture  
 was annealed by heating to 70 °C for 5 minutes, cooled slowly to room temperature and then placed on ice.  
 50 To this cold annealing mixture was added 1.5  $\mu$ l of 10X elongation buffer B (0.2 M Tris-HCl, 0.1 M MgCl<sub>2</sub>,  
 0.1 M DTT pH 7.5, Zoller and Smith, *ibid.*), 6  $\mu$ l of deoxynucleotide triphosphates (2.5 mM each dNTP), 1  
 $\mu$ l of T<sub>4</sub> DNA ligase, 1  $\mu$ l of DNA polymerase Klenow fragment, 1  $\mu$ l ATP (10 mM), and 5  $\mu$ l of water. This  
 mixture was incubated for 16 hours at 18 °C. This reaction mixture was then diluted 20-fold with water, and  
 2  $\mu$ l of the dilute mixture was used to transform *E. coli* JM107 cells. The resulting phage plaques were  
 55 transferred to nitrocellulose discs by the procedure of Benton and Davis (*Science* 196: 180, 1977) and  
 screened with <sup>32</sup>P-labeled ZC506 which was labeled with T<sub>4</sub> polynucleotide kinase under standard  
 conditions. The hybridization of the <sup>32</sup>P-ZC506 to the filters was performed at 37 °C in 6X SSC (0.9 M NaCl,  
 0.09 M Na Citrate, pH 7.2), 100  $\mu$ g/ml carrier DNA, 0.05% sodium pyrophosphate. Following hybridization,

the filters were washed at 54 °C in 6X SSC, 0.1% SDS. Phage plaques giving strong autoradiographic signals were picked and RF DNA made and analyzed for the presence of a new Sst I restriction endonuclease site. The sequence around the Sst I site was also confirmed by DNA sequence analysis. The Pst I-Xba I subclone now containing an Sst I site was ligated back into Pst I-Xba I digested pVSB and the resulting plasmid termed pSB1. Plasmid pSB1 encodes two amino acid changes (Leu to Glu and Asp to Leu) in the alpha-factor leader just upstream of the Lys-Arg. The resulting junction sequence is:  $\alpha$ -factor . . . Glu Leu Lys Arg Ser . . . B-chain. The B-chain coding sequences of pSB1 are thus flanked by an Sst I site at the 5' end and an Xba site at the 3' end.

## EXAMPLE VII

### Construction of Variants and Derivatives of the B-chain

#### A. Construction of a Human B-chain Expression Unit.

The B-chain construction pVSB described in Example IV above encodes the monkey B-chain amino acid sequence derived from the v-sis gene. This B-chain amino acid sequence differs from the human B-chain amino acid sequence at four positions: 6, 7, 101 and 107. These amino acid differences are largely conservative and not likely to affect the biological activity of the B-chain.

In order to express authentic human B-chain, the monkey-specific amino acids were changed to the human sequence by incorporating synthetic oligonucleotide duplexes, encoding the human amino acids into the pVSB construction. In this case, the preferred starting vector was pSB1 (described above), which has an Sst I site introduced at the  $\alpha$ -factor-B-chain junction. The DNA sequences between this Sst I site and the Bgl II site at amino acid #24 (Figure 9) were replaced to encode the human amino acids threonine and isoleucine at positions 6 and 7. Four oligonucleotides, ZC685, ZC686, ZC687 and ZC688 (Table 2), were designed to replace the pSB1 sequences between Sst I and Bgl II. ZC685 and ZC686 were annealed to form one duplex, and ZC687 and ZC688 were annealed to form the other. These two annealed duplexes were then ligated with Sst I-Bgl II digested pSB1 vector. The resulting plasmid was confirmed by DNA sequencing and termed pSB11.

The amino acid changes at the B-chain carboxyl end were made in a similar fashion. Plasmid pSB11 is digested with Sph I and Xba I and the sequences in this region were replaced by a synthetic DNA duplex designed to encode human amino acids threonine at position 101 and proline at position 107. Oligonucleotides ZC675 and ZC676 were annealed and ligated into Sph I-Xba I digested pSB11 under standard conditions. The construction was confirmed by DNA sequencing and termed pB12. This plasmid encodes the authentic human B-chain amino acid sequence.

Alternatively, the human B-chain amino acid sequence could be expressed by performing site-specific mutagenesis on the pVSB plasmid to change the four amino acids in question or by expressing a human B-chain cDNA sequence.

#### B. Monomer-Size B-chain Mutant.

Biologically active PDGF, as it is isolated from platelets or transformed cells in culture, is a disulfide bonded dimer. Chemical reduction of this dimer molecule destroys its biological activity. Surprisingly, it has been found that changing B-chain cysteine residues which are involved in interchain disulfide bonds to other amino acids or changing amino acids near these cysteine residues allows the B-chain polypeptide to fold properly but not permit interchain disulphide bonds to occur. This results in a monomer B-chain folded in a confirmation which permits binding to the PDGF cell surface receptor. Changing B-chain amino acid lysine 98 to a leucine has resulted in a molecule which is active as a monomer. This molecule is made as follows.

Plasmid pVSB (Figure 8) is digested with Sph I and Xba I, and the DNA sequences between these restriction sites are replaced with a synthetic oligonucleotide duplex. The duplex is formed by annealing oligonucleotides analogous to ZC299 and ZC300, but containing a leucine codon at position 98 instead of a lysine codon. All the other codons in this region are preserved and encode B-chain amino acid sequence. The annealed duplex has a 5' Sph I cohesive end and a 3' Xba I cohesive end and is ligated into the Sph I-Xba I digested pVSB. This B-chain mutant is termed pSB6.

When this construction is cloned into the pMPOT2 plasmid (then termed pSB6m) and transformed into yeast, it produces mitogenically active material. Furthermore, when the expressed mitogenic material is fractionated on a polyacrylamide gel and subsequently eluted from slices of the gel, mitogenically active

material is found in the monomer size range of the gel. This demonstrates that it is possible to produce a biologically active PDGF monomer by altering cysteine residues or the environment around them. Mutagenesis of other cysteine residues in the molecule may therefore be expected to lead to a similar result.

5

#### C. Truncated Amino Terminal B-chain Mutant.

During biosynthesis of the B-chain in the yeast expression system, the  $\alpha$ -factor prepro polypeptide is removed from the B-chain by proteolytic processing at the basic dipeptide, Lys-Arg. Another basic dipeptide Arg-Arg occurs 27 amino acids downstream in the B-chain (Figure 9). It was of interest to know if the yeast processing machinery would process the B-chain at this internal site and still yield an active protein. In order to drive the proteolytic processing to occur at the internal Arg-Arg site, the Lys-Arg at the  $\alpha$ -factor-B-chain boundary was removed by oligonucleotide directed mutagenesis.

The mutagenesis was performed essentially as described for the construction of pSB1 above. The Pst I-Xba I fragment of pVSB (Figure 8) was subcloned into the M13 phage vector mp19 and single-stranded template DNA prepared. In this case, the mutagenic oligonucleotide used, ZC505 (Table 2), was designed to change the  $\alpha$ -factor Lys-Arg residues to Gly-Leu and to introduce a new Pvu II restriction site. The mutagenesis reactions were carried out as described above for pSB1 and the resulting mutants screened for the new Pvu II site and then confirmed by DNA sequence analysis. The mutagenized Pst I-Xba I fragment was subcloned back into the B-chain expression unit (pVSB) and the new plasmid termed pSB3.

20

### EXAMPLE VIII

#### Construction of Variants and Derivatives of the A-chain

25

##### A. Synthesis of the A-chain Amino Terminus and Construction of A-B Hybrid Fusions.

The A-chain coding sequences were inserted into the pSB1 vector as short synthetic oligonucleotide duplexes designed to encode known A-chain amino acid sequence (Johnson et al., *EMBO J.* 3: 921-928, 1984). ZC545 and ZC546 (Table 2) were annealed, creating a short duplex DNA fragment with a 5' Sst I cohesive end, a unique Mlu I restriction site, and a 3' Bgl II cohesive end. This duplex was cloned into Sst I and Bgl II-digested pSB1. One  $\mu$ l of pSB1 vector (0.15 pmole) was combined with 1  $\mu$ l of ZC546 (~1.6 pmole) and 0.6  $\mu$ l of ZC545 (~1.5 pmole), plus 0.25  $\mu$ l of 0.3 M NaCl (final NaCl concentration in the annealing reaction is 30 mM) and the mixture was heated to 60°C for five minutes. After heating, the mixture was brought to room temperature and then placed on ice. Then 0.5  $\mu$ l of 10X ligase buffer (0.5 M Tris-HCl, 0.1 M MgCl<sub>2</sub>, 2 M DTT, 0.01 M ATP, pH 7.8), 0.1  $\mu$ l of T<sub>4</sub> DNA ligase (New England Biolabs) and 2.5  $\mu$ l of water were added and this ligation mixture was diluted and used to transform *E. coli* HB101 cells. Ampicillin-resistant, plasmid-bearing colonies were picked, grown up and plasmid DNA isolated by the "miniprep" method of Ish-Horowicz and Burke (*Nuc. Acid Res.* 9: 2989-2998, 1981). The plasmids were analyzed for the presence of an Sst I-Bgl II insert and a new Mlu I restriction site and confirmed by DNA sequence analysis. The ZC545-546 duplex encoded A-chain amino acids alanine 8 through tryptophan 17 (Figure 9) and the resulting plasmid was termed pA1.

ZC547 and ZC548 (Table 2) were annealed to create a second short Sst I-Bgl II fragment encoding A-chain amino acids serine 1 through arginine 13 (Figure 9) and also containing an Mlu I restriction site. The ZC547-548 duplex was separately cloned into Sst I and Bgl II digested pSB1. One  $\mu$ l of pSB1 (1.5 pmole) digested with Sst I and Bgl II was combined with 2  $\mu$ l of ZC547 (1 pmole) and 2  $\mu$ l of ZC548 (1 pmole) plus 0.25  $\mu$ l of 0.3 M NaCl and the mixture was heated to 50°C for five minutes. After heating, this annealing mixture was brought to room temperature and then placed on ice. Then 0.6  $\mu$ l of 10X ligase buffer and 0.1  $\mu$ l of T<sub>4</sub> DNA ligase (New England Biolabs) were added and the reaction was incubated overnight at 12°C. An aliquot of this ligation reaction was diluted and used to transform *E. coli* HB101 cells and the resulting plasmids were screened and analyzed as described above for pA1. In this case, the resulting plasmid was termed pA2.

The overlapping pA1 and pA2 A-chain coding regions were joined at the unique Mlu I restriction site using conventional techniques. Plasmid pA2 was digested with Mlu I and Bam HI and the ~1.4 kb vector (pUC containing) fragment was isolated by agarose gel electrophoresis and extracted from the agarose with CTAB (Langridge et al., *Anal. Biochem.* 103: 264-271, 1980). Plasmid pA1 was also digested with Mlu I and Bam HI and the ~800 base pair fragment, encoding A-chain amino acids 13 through 17 fused to B-chain amino acids 24 through 109 followed by the TPI terminator, was isolated and extracted as above. Equimolar

55

amounts of these two fragments were ligated under standard conditions and an aliquot used to transform *E. coli* HB101 cells. Plasmids obtained from ampicillin-resistant colonies were analyzed by restriction enzyme digestion for the correct fragments and confirmed by DNA sequencing. The resulting plasmid termed pA3 thus encoded a hybrid protein beginning with A-chain amino acids 1 through 17 followed in frame by B-chain amino acids 24 through 109. The Cla I-Bam HI fragment of pA3 containing the entire expression unit was cloned into pMPOT2 and the resulting plasmid pA3m was transformed into yeast.

Further addition of A-chain amino acids to the A-B hybrid was accomplished in a similar fashion. Plasmid pA3 was digested first with Asp718, which cuts the plasmid once in the A-chain sequence at proline codon 7, and with Bam HI, and the hybrid amino acid coding fragment subcloned into pUC118. This subclone was termed pA3N and was subsequently digested with Bgl II and Bst XI. Bgl II cuts at the boundary of the A- and B-chain sequences in the hybrid and Bst XI cuts approximately 40 base pairs downstream in the B-chain. The vector fragment (pUC-containing) from this digest was isolated by agarose gel electrophoresis and extracted with CTAB. One picomole each of oligonucleotides ZC692 and ZC693 (Table 2) was annealed to form a short DNA duplex with a 5' Bgl II end and a 3' Bst XI end. This duplex encoded A-chain glutamic acid 18 through phenylalanine 31 and was ligated with 0.1 picomole of Bgl II-Bst XI-digested pA3N. The ligation was performed overnight and the ligated products transformed into *E. coli* MV1193 cells. The resulting plasmid termed pA6N now has extended the A-chain amino acid sequence to the Bst XI site at amino acid A31 followed by B-chain amino acids B38 through B109.

Plasmid pA6N was then digested with Asp718 and Bam HI and the A-B hybrid fragment cloned back into Asp718-Bam HI digested pA3m. This new A-B hybrid plasmid is termed pA6m and encodes A-chain amino acid sequence up to amino acid 40 because the Bst XI site lies at the start of a region of high homology between A- and B-chains.

#### B. Construction of A-B-A Hybrid Fusions.

Since the A- and B-chains of PDGF are so homologous in structure and function, there are likely to be several biologically active hybrid molecules which can be made between the two. A number of examples containing amino terminal A-chain sequence followed by B-chain amino acids are described above. Another example of this concept would be to construct a hybrid protein which contained A-chain amino acid sequence at the amino and carboxyl termini and B-chain sequence in the middle.

A preferred embodiment would use plasmid pA6, which encodes the hybrid protein A1-17, B24-109, and to exchange A-chain for B-chain amino acid sequence at its carboxyl end. In this case, the B-chain coding region is digested with the restriction endonuclease Sph I, which cuts in B-chain codons 96 and 97 (Figure 9). The plasmid pA6 is cut again with Xba I, which cuts immediately 3' of the translation termination codon. This sequence is then replaced with two oligonucleotides which, when annealed, form a duplex with 5' and 3' Sph I and Xba I cohesive ends, respectively, and contain A-chain codons (Figure 9). The two oligonucleotides, ZC ABA-1 and ZC ABA-2, are shown in Table 2. These two oligonucleotides are annealed by heating to 65°C and slow cooling as described above. The annealed duplex is then ligated into Sph I-Xba I digested pA6 plasmid which has been isolated by agarose gel electrophoresis. The ligated product is transformed into *E. coli* MV1193 cells and transformed colonies obtained on ampicillin plates. In this case, no new restriction sites are introduced by the new A-chain duplex, so the construction is confirmed by DNA sequence analysis.

#### C. Construction of an A-chain Cysteine Mutant.

As can be seen from Figure 9, both the A- and B-chains of PDGF contain eight cysteine residues which are capable of forming disulphide bonds. It can also be seen from Figure 9 that these cysteine residues are in analogous positions in the two polypeptides and hence may participate in similar disulfide arrangements in and between the two chains and even between two different chains (A and B). It has been known for several years that chemical reduction of the disulfide-bonded PDGF dimer to monomers destroys its biological activity. It is of interest to know which of the cysteine residues in question are involved in disulfide bonds of both the intra- and intermolecular type. It is very likely that the role of each cysteine will be analogous in both A- and B-chains.

The first cysteine residue in the A-chain occurs at position #10, which is analogous to #16 in the B-chain (Figure 9). The A-B hybrid pA3 (described above) encodes A-chain amino acids 1-17, followed by B-chain. The synthetic strategy leading to construction of pA3 incorporated unique restriction sites flanking the cysteine at residue A10. An Asp718 and an Mlu I restriction site were placed 5' and 3', respectively, to the A10 cysteine codon approximately 20 base pairs apart. Two oligonucleotides (ZC671 and ZC672, Table 2)

were synthesized and annealed to form a short DNA duplex with a 5' Asp718 cohesive end and a 3' Mlu I cohesive end. This duplex encodes a serine residue in place of cysteine A10. Plasmid pA3 was digested with Asp718 and Mlu I and the large vector (pUC containing) fragment isolated by agarose gel electrophoresis. Equimolar amounts of the vector and the ZC671-672 duplex were ligated under standard conditions as described above and then transformed into *E. coli* MV1193 cells. Plasmid (miniprep) DNA was prepared from the resulting transformants and screened for a new Pvu II site present in the ZC671-672 duplex. The duplex region of the plasmid is then confirmed by DNA sequence analysis. The resulting plasmid, termed pA5, encodes an A-B hybrid protein with A-chain amino acids 1-17 at the amino terminus, but residue 10 is a serine instead of a cysteine. The remaining amino acids of the pA5 hybrid are the normal B-chain residues (Glu 24 through Thr 109).

#### D. Complete Synthesis of the A-chain Gene.

The remainder of the A-chain gene was synthesized with oligonucleotides in a fashion very similar to that described above. Many strategies could be designed to accomplish this task. One such strategy is described below. The oligonucleotides used in this strategy are shown in Table 2 and their design reflects optimal codon usage for *Saccharomyces cerevisiae*. In this strategy, the remainder of the A-chain gene was synthesized with unique restriction sites introduced in order to facilitate subcloning and sequencing the synthetic oligonucleotide sequences. All the oligonucleotides were synthesized on an Applied Biosystems 380-A DNA synthesizer. Oligonucleotides ZC752 and ZC753, each 87mers, were annealed and subcloned as a Hind III-Xba I fragment encoding A-chain amino acids 77-104. ZC752 and ZC753 (1.25 picomole each) were annealed in 5  $\mu$ l of 40 mM NaCl by heating to 65°C for 15 minutes and then allowing the mixture to come to room temperature and putting on ice. One-tenth of this annealed duplex (.0125 picomole) was ligated into both pUC118 (.07 pmole) and M13 mp18 (.02 picomole) which were previously digested with Hind III and Xba I. The ligated mixtures were used to transform the appropriate *E. coli* host strain (JM107 in the case of M13 mp18 and MV1193 in the case of pUC118) and the resulting plasmid or RF DNAs analyzed by restriction endonuclease digestion and DNA sequencing.

The oligonucleotides ZC746 + 747, 748 + 749, and 750 + 751 were designed to form short duplexes with cohesive ends which when joined would constitute the sequence between the Bst XI site at A31 and the Hind III site at A77. The oligonucleotides were phosphorylated with <sup>32</sup>P and T<sub>4</sub> polynucleotide kinase under standard conditions. The pairs ZC746 + ZC747, ZC748 + ZC749, and ZC750 + ZC751 were each annealed by combining 2.5 pmole of each oligonucleotide in 5  $\mu$ l of 40 mM NaCl, heating to 65°C for 15 minutes, allowing to come to room temperature, and putting on ice. The three annealing mixtures were combined (now 15  $\mu$ l) and ligated in a final volume of 20  $\mu$ l. The ligated products were electrophoresed in a 4% NuSieve agarose gel (FMC Corporation) in TBE buffer (90 mM Tris, 90 mM boric acid, 2 mM disodium EDTA) followed by autoradiography. The ~140 base pair fragment corresponding to the three correctly ligated duplexes was cut out of the gel and extracted with CTAB. This fragment, together with the previously cloned Hind III-Xba I fragment, was ligated into the Bst XI-Xba I digested pA6N vector. The resulting plasmid was termed pA6N+. Plasmid pA6N+ was then digested with Asp718 and Xba I and the A-chain coding fragment cloned back into pA3. This plasmid pA7 encodes the entire mature A-chain.

For purposes of yeast expression, a preferred embodiment would employ oligonucleotides ZC748 and ZC749. These encode a glutamine at position A-48 instead of an asparagine. This change destroys the N-linked glycosylation site which can be aberrantly glycosylated in yeast. Oligonucleotides designed to preserve the N-linked glycosylation site could also be used.

The strategy employing total gene synthesis described above is desirable because the amino acid sequence of the A-chain is known and the codon usage can be optimized for yeast. Alternatively, an A-chain cDNA sequence could be expressed in yeast or other eukaryotic cells, provided the cDNA was appropriately incorporated into a suitable expression vector. An A-chain cDNA could be obtained from a variety of mammalian cell lines by conventional techniques (Betsholtz et al., *Nature* 320, 695-699, 1986.)

#### E. Construction of A-chain Amino Terminal Truncated Mutant

During biosynthesis of the A-chain protein in the yeast expression system, the  $\alpha$ -factor prepro-peptide is removed from the A-chain by proteolytic processing at the basic dipeptide Lys-Arg, alpha factor amino acid residues #84 and #85. In order to drive the proteolytic processing to occur at an internal A-chain site, the Lys-Arg at the  $\alpha$ -factor-A-chain boundary is removed and an internal Arg-Arg created by oligonucleotide directed mutagenesis.

The Lys-Arg removal mutagenesis is performed essentially as described for the construction of pSB1 above. The Pst I-Xba I fragment of pVSB (Figure 8) is subcloned into the M13 phage vector mp19 and single-stranded template DNA is prepared. In this case, the mutagenic oligonucleotide is designed to change the  $\alpha$ -factor Lys-Arg residues to Gly-Leu and to introduce a new Pvu II restriction site. The mutagenesis reactions are carried out as described above for pSB1 and the resulting mutants are screened for the new Pvu II site and then confirmed by DNA sequence analysis. The mutagenized Pst I-Xba I fragment is subcloned back into the A-chain expression unit (designated pA7).

In order to introduce a dibasic peptide site into the A-chain coding sequence, oligonucleotide-directed mutagenesis is employed as described above. Amino acid residue #22 in the A-chain is a serine, while #21 is an Arg. In this case, the mutagenic oligonucleotide is designed to change the Ser #22 to an Arg, creating the sequence Arg-Arg at positions #21 and #22. This new dibasic site in the A-chain occurs in a position precisely analogous to one, which is normally present in the B-chain (Figure 9). By expressing this mutant construction from the  $\alpha$ -factor leader lacking the dibasic processing site, the resultant A-chain molecule should be processed internally at the new Arg-Arg and be secreted as a truncated polypeptide.

#### EXAMPLE IX

##### Insertion of Expression Unit Constructions into pMPOT2

Each of the molecules constructed in Examples VI-VIII above was introduced back into the basic expression unit pVSB or pSB1 if the Sst I site was employed. Then each of them was ultimately cloned into the yeast plasmid pMPOT2 (Example IV). In each case, this was done by removing the expression unit as a single fragment from pVSB or pSB1 by Cla I-Bam HI digestion. The Cla I-Bam HI fragment of each was isolated by agarose gel electrophoresis and cloned into pMPOT2 which had been digested with Cla I and Bam HI. The names of the resulting plasmids are then amended with a lower case "m," e.g., pA2 becomes pA2m.

Each of the mPOT constructions was then transformed into the yeast strain E18-#9 (Example VI).

#### EXAMPLE X

##### A-B Heterodimer Expression Construction

PDGF is a disulfide-bonded dimer, and as isolated from platelets, is composed of two amino acid chains, on A-chain and a B-chain. It is presumed that this material is in the form of an A-B heterodimer. There are now a number of examples of PDGF homodimers composed of either A-or B-chain (Kelly et al., EMBO J. 4: 3399-3405 1985; Stroobant and Waterfield, EMBO J. 3: 2963, 1984; and Heldin et al., Nature 319: 511, 1986). While platelet PDGF is still thought to be a heterodimer, these data raise the possibility that it may actually be a mixture of A-A and B-B homodimers.

Having expressed biologically active A and B forms of PDGF in the yeast expression system, it is possible to introduce both an A- and a B-chain expression unit into the same yeast cell and to identify A-B heterodimers among the biologically active products. This can be done by introducing the respective expression units into the yeast cell on different plasmids, possibly with different selectable markers. Using this strategy, it may be difficult to control the relative copy numbers of the two plasmids and this may result in disproportionate amounts of the A- and B-chain polypeptides in the cell. A preferred strategy would be to put both the A-chain and B-chain expression units on the same plasmid. In this way, their copy numbers would always be equal.

There are numerous ways to incorporate both expression units into the same plasmid. Within the present invention, the B-chain expression unit from plasmid pVSB (Figure 8) was removed by complete digestion with Bam HI followed by partial digestion with Bgl II. The fragment corresponding to the expression unit (TPI promoter-MF $\alpha$ 1-B-chain-terminator) was isolated by agarose gel electrophoresis and subcloned into the Bam HI site of pUC18. The orientation of the insert in the resulting subclones was established by conventional restriction enzyme digestions. A subclone in which the Bgl II end of the insert was adjacent to the Sal I site in the polylinker was chosen for the next step. This subclone was digested with Sal I and Bam HI and the insert fragment isolated. This B-chain fragment was then ligated into plasmid pA7m, which had been digested with Sal I and Bam HI. The resulting plasmid pAB2m contains both the A- and the B-chain expression units oriented tail to tail. This plasmid is then transformed into yeast strain E18-#9.

## EXAMPLE XI

## Biological Activity Assays

## 5 A. Radioreceptor Assay (RRA) for PDGF.

The radioreceptor assay for PDGF (Bowen-Pope and Ross, J. Biol. Chem. 257: 5161, 1982) is a specific and sensitive (0.2-2 ng/ml PDGF) method for detecting biologically active PDGF-like material in yeast. In this assay, PDGF-like material is tested for its ability to compete with purified, radio-labeled <sup>125</sup>I-PDGF for  
 10 binding sites on cell surface PDGF receptors. Results are interpreted by comparison to a standard curve generated with purified, unlabeled PDGF. Comparison of results obtained with other assay methods (e.g., ELISA) provides an indication of the strength of the receptor/ligand interaction in addition to quantitation of the material bound. The assay is conducted as follows: Subconfluent monolayers of diploid human fibroblasts are prepared by plating  $1.5 \times 10^4$  cells per 2 cm<sup>2</sup> culture well in Costar 24-well cluster trays in  
 15 Dulbecco's Modified Eagles Medium (DMEM) supplemented with 1% human plasma-derived serum (PDS). Cultures are set on an ice tray and rinsed once with ice-cold binding rinse (Ham's medium F-12 buffered at pH 7.4 with 25 mM HEPES and supplemented with 0.25% BSA). One ml/well of test substance in binding medium is added and the cultures incubated in a refrigerated room on an oscillating platform for 3 to 4 hours. The trays are then placed on ice, aspirated, rinsed once with cold binding rinse and incubated for  
 20 one hour as above with 1 ml/well binding medium containing 0.5 ng/ml <sup>125</sup>I-PDGF. Labeling is terminated with four rinses of binding rinse and cell-associated <sup>125</sup>I-PDGF determined by extraction with solubilization buffer. Standard curves are obtained using 0, 0.05, 0.1, 0.2, 0.4, and 0.8 ng/ml purified PDGF and test samples compared to these values.

PDGF receptor binding by CM-Sephadex media concentrates from yeast transformants containing  
 25 plasmids pVSBm and pMPOT2 was compared to receptor binding by authentic PDGF. After concentration by binding to and elution from CM-Sephadex, the pVSBm concentrate was normalized to PDGF equivalents in an ELISA using polyclonal goat antibody to PDGF. The RRA results were interpreted by comparison to a standard curve generated with purified, unlabeled PDGF, as shown in Figure 10. Media from cultures transformed with the pVSBm constructions are shown to compete with <sup>125</sup>I-PDGF for binding to the PDGF  
 30 receptor. Media from yeast cells transformed with pMPOT2 do not compete with radio-labeled PDGF for receptor binding.

## B. Mitogenesis Assay.

35 The ability of PDGF to stimulate DNA synthesis and cell growth in culture was the basis for its definition and discovery. <sup>3</sup>H-Thymidine incorporation into DNA of cultured cells responsive to PDGF (Raines and Ross, Meth. in Enzymology 109: in press) is a preferred method for demonstrating the biological activity of PDGF-like molecules produced in yeast.

Straight spent media test samples or concentrates of spent media or test samples in 10 mM acetic acid  
 40 (up to 100  $\mu$ l/well) are added to quiescent cultures of mouse 3T3 cells in 2cm<sup>2</sup> Costar 24-well culture dishes ( $2-3 \times 10^8$  cells/well in 1 ml). Quiescent test cultures can be obtained by plating the cells in 10% serum and allowing them to deplete the medium, 4 to 5 days. The test samples are removed from the wells at 20 hours and replaced with 0.5 ml of fresh medium per well containing 2 uCi/ml [<sup>3</sup>H]-Thymidine and 5% (v/v) calf serum. After an additional 2-hour incubation at 37°C the cells are harvested by: aspirating off the  
 45 medium; washing the wells twice each with 1 ml of ice-cold 5% TCA; solubilizing TCA-insoluble material in 0.8 ml 0.25N NaOH with mixing; and counting 0.6 ml of this solution in 5 ml Aquasol in a liquid scintillation counter. Fold stimulation over control wells (100  $\mu$ l of 10 mM acetic acid alone) is determined (normally 30- to 50-fold maximal stimulation) and compared to a standard curve obtained using purified PDGF preparations.

50 The A-chain homodimer and the B-chain homodimer have been purified to homogeneity, quantitated by amino acid analysis, and found to have substantially equal specific activity in the mitogenesis assay.

## EXAMPLE XII

## Optimization of Protein Expression

## 5 A. Optimized B-Chain Expression Construction

The DNA sequences encoding the alpha-factor leader and PDGF B-chain were modified to contain yeast-optimal codons and to encode wild-type alpha-factor as well as authentic human B-chain. This restored the alpha-factor sequence which had been altered in previous constructions and allowed the optimization of B-chain expression levels.

The codon-optimized alpha-factor leader sequence was obtained from an expression vector containing the gene for the insulin analog B(1-29)-Ala-Ala-Lys-A(1-21) (Markussen et al., EP 163,529). An Eco RI-Xba I fragment comprising the alpha-factor pre-pro and insulin sequences was cloned into Eco RI, Xba I digested pUC118 (obtained from J. Viera and J. Messing, Waksman Institute of Microbiology, Rutgers, Piscataway, N.J.) and single-stranded template DNA was prepared. This template was then mutagenized according to the two-primer method (Zoller and Smith, *DNA* 3: 479-488, 1984) using the mutagenic oligonucleotide ZC862 (5' CGA ATC TTT TGA GCT CAG AAA CAC C 3'). The mutagenesis resulted in the creation of an Sst I site at the 3' end of the alpha-factor leader. A correctly altered plasmid was selected and designated pKP23. The leader sequence was excised from pKP23 by digestion with Eco RI and Sst I, and the leader fragment was subcloned into pIC19 (Marsh et al., *Gene* 32: 481-486, 1984). The resultant plasmid was designated pKP24.

The human B-chain sequence was obtained from plasmid pB12 (Example VII A). pB12 was digested with Sst I and Xba I and the B-chain fragment was recovered. Plasmid pKP10, comprising the TPI promoter--alpha-factor--VSB--TPI terminator of pSB1 (Example VI) inserted into a pBR322 vector lacking an Eco RI site, was digested with Sst I and Xba I to remove the VSB sequence. The pB12 B-chain sequence and the pKP24 alpha-factor sequence (Eco RI-Sst I) were then inserted into the pKP10 expression unit. The resultant plasmid was designated pKP26.

The Sst I site introduced into the alpha-factor leader to facilitate the construction of pKP26 was then removed to restore the wild-type coding sequence. Plasmid pKP26 was digested with Eco RI and Xba I and the alpha-factor--B-chain fusion sequence was recovered. This fragment was cloned into pUC118 and single-stranded template DNA was isolated. The template was mutagenized by the two primer method using the mutagenic oligonucleotide ZC1019 (5' ACC CAA GGA TCT CTT GTC CAA AGA AAC ACC TTC TTC 3'). A correctly mutagenized plasmid was designated pKP32.

The entire expression unit was then reconstructed. Plasmid pKP32 was digested with Eco RI and Xba I and the alpha-factor--B-chain fragment was recovered. This fragment was inserted into Eco RI, Xba I cut pKP25 to construct pKP34. Plasmid pKP34 was digested with Cla I and Bam HI and the expression unit was recovered. This fragment was inserted into Cla I, Bam HI digested pMPOT2 to construct pKP36.

The B-chain sequence was then codon optimized. An internal Bgl II--Sph I fragment of the B-chain sequence of pKP36 was replaced with a sequence assembled from the oligonucleotides shown in Table 4. The pMPOT2-based expression vector containing the fully optimized expression unit was designated pB170m.

## B. Optimized A-Chain Expression Construction

The codon-optimized A-chain sequence from plasmid pA7 (Example VIII D) was combined with the codon-optimized alpha-factor leader sequence in a series of construction steps parallel to those described above for B-chain. The alpha-factor sequence of pKP24 was combined with the pA7 A-chain sequence and Eco RI, Xba I cut pKP10 to construct pKP27. Plasmid pKP27 was digested with Eco RI and Xba I and the alpha-factor--A-chain fragment was cloned into pUC118.

Mutagenesis, using the oligonucleotide ZC1018 (5' TTC GAT AGA TCT CTT GTC CAA AGA AAC ACC TCC TTC 3'), was carried out as described above to remove the Sst I site and restore the wild-type alpha-factor sequence. The corrected plasmid was designated pKP31.

A codon-optimized expression vector was then constructed. Plasmid pKP31 was digested with Eco RI and Xba I and the alpha-factor--A-chain fragment was joined to Eco RI, Xba I cut pKP24. The resultant vector, designated pKP33, contained the entire expression unit. Plasmid pKP33 was digested with Cla I and Bam HI and the expression unit fragment was recovered. This fragment was inserted into Cla I, Bam HI cut pMPOT2 to construct the expression vector pKP35.

## C. Expression of A-Chain and B-Chain

*S. cerevisiae* strain XB13-5B was separately transformed with plasmids pB170m and pKP35 according to standard procedures. Transformants were cultured in glucose media at 30 °C with agitation. Cultures were harvested, cells were removed by centrifugation, and protein was purified from the supernatants as described below.

*S. cerevisiae* strain XB13-5B transformants containing plasmids pB170m and pKP35 have been deposited with American Type Culture Collection, Rockville, Md. 20852, U.S.A.

## D. Protein Purification

Yeast culture supernatants (12 liters), prepared as described above, were concentrated on an Amicon RA2000 ultrafiltration membrane at a flow rate of 60 ml/min to a volume of 350 ml. The buffer was exchanged with 25 mM Na acetate pH 5.5 containing 0.1% NaN<sub>3</sub>. The concentrated samples were centrifuged at 15,000 rpm for 20 min and stored at -20 °C.

The frozen samples were thawed, centrifuged at 15,000 rpm for 20 min and fractionated on an S-Sepharose column (Pharmacia). 300 ml samples were loaded onto a 30 ml column at a flow rate of 2 ml/min. The column was then washed with 25 mM Na acetate pH 5.5 containing 0.1% NaN<sub>3</sub>. The column was eluted at a rate of 2 ml/min using the following elution program: 20 min with 20 mM Na phosphate pH 7.3 containing 0.1% NaN<sub>3</sub>; 30 min with 20 mM Na phosphate pH 7.3, 0.2 M NaCl; 50 min with 20 mM Na phosphate pH 7.3, 0.5 M NaCl; 20 min with 20 mM Na phosphate pH 7.3, 1M NaCl. A- and B-chain polypeptides eluted at 0.5 M NaCl. Fractions were assayed for mitogenic activity and by gel electrophoresis. Mitogenically active fractions were pooled and the pH adjusted to 6.0.

Final purification was accomplished by high-performance liquid chromatography (HPLC). The pooled fractions from the Sepharose chromatography were passed over a MicroPak C-18 column at a flow rate of 1 ml/min. The PDGF polypeptides were eluted using a gradient of Buffer B (0.1% TFA in CH<sub>3</sub>CN) in Buffer A (0.1% TFA in H<sub>2</sub>O). The elution program was:

| Time (min.) | % Buffer B |
|-------------|------------|
| 0           | 0          |
| 17.5        | 35         |
| 32.5        | 50         |
| 33.0        | 100        |

0.5 ml fractions were collected and assayed for mitogenic activity, and active fractions were pooled.

TABLE 4

|       |                                                                   |
|-------|-------------------------------------------------------------------|
| ZC886 | GGCCACCATGTGTTGAAGTTCAAAGATGCTCGGGTTGTTGTAACAACAGAAAC<br>GTTCAATG |
| ZC887 | TCGACATTGAACGTTTCTGTTGTTACAACAACCCGAGCATCTTTGAACTTCAA<br>CACATG   |
| ZC888 | GATCTCTAGAAGATTGATCGACAGAACCAACGCCAACTTCTTGGTTT                   |
| ZC889 | GTGGCCAAACCAAGAAGTTGGCGTTGGTTCTGTGATCAATCTTCTAGA                  |
| ZC907 | CGTTAGAAAGAAGCCAATCTTCAAGAAGGCTACCGTTACCCTCGAGGACCACT<br>TGGCATG  |
| ZC908 | TCGACCAACCCAAGTTCAATTGCGGCCGGTTCAAGTGC GCAAGATCGAAAT              |
| ZC909 | CTAACGATTTGATCTTGC GCACTTGAACCGGCCGCAATTGAACTTGGGTTGG             |
| ZC910 | CCAAGTGGTCCTCGAGGGTAACGGTAGCCTTCTTGAAGATTGGCTTCTTT                |

## Claims

1. A recombinant protein homodimer having two disulfide-bonded polypeptide chains, said chains selected from the group consisting of:
  - (a) the A-chain of human PDGF from amino acid 9 to amino acid 104;
  - (b) the A chain of human PDGF from amino acid 9 to amino acid 95;
  - (c) the A-chain of human PDGF from amino acid 1 to amino acid 95; and
  - (d) the A-chain of human PDGF from amino acid 1 to amino acid 104,
 said protein having human PDGF mitogenic activity.
2. A recombinant protein homodimer according to claim 1, further characterized by the substitution of at least one cysteine residue at position 37, 46 or 47 by another amino acid residue.
3. A recombinant protein homodimer according to claim 2, wherein said other amino acid residue is a serine residue.
4. A recombinant protein having two disulfide-bonded polypeptide chains, wherein at least one of said chains is a mosaic of amino acid sequences of the A- and B-chains of human PDGF, wherein the mosaic chain is selected from the group consisting of:
  - (a) A-chain amino acids 1-17 joined to B-chain amino acids 24-109;
  - (b) A-chain amino acids 1-31 joined to B-chain amino acids 38-109;
  - (c) A-chain amino acids 1-17 joined to B-chain amino acids 24-97 joined to A-chain amino acids 92-104;
 and wherein the second chain is selected from the group consisting of:
  - (d) the A-chain of human PDGF from amino acid 9 to amino acid 104;
  - (e) the A chain of human PDGF from amino acid 9 to amino acid 95;
  - (f) the A-chain of human PDGF from amino acid 1 to amino acid 95;
  - (g) the A-chain of human PDGF from amino acid 1 to amino acid 104;
  - (h) the B-chain of human PDGF from amino acid 15 to amino acid 109;
  - (i) the B-chain of human PDGF from amino acid 1 to amino acid 101;
  - (j) the B-chain of human PDGF from amino acid 15 to amino acid 101; and
  - (k) the B-chain of human PDGF from amino acid 1 to amino acid 109,
 said protein having human PDGF mitogenic activity.
5. A recombinant protein according to claim 4, further characterized by the substitution of at least one cysteine residue at a position corresponding to A-chain position 37, A-chain position 46, A-chain position 47, B-chain position 43, B-chain position 52 or B-chain position 53 by another amino acid residue.
6. A recombinant protein according to claim 5, wherein said other amino acid residue is a serine residue.
7. A recombinant protein according to any of claims 1 - 6, wherein said protein is unglycosylated.
8. A therapeutic composition comprising a protein according to any of claims 1 - 7 and a physiologically acceptable carrier.
9. A therapeutic composition according to claim 8, wherein said carrier is selected from albumin, sterile water, and saline.
10. A therapeutic composition according to claim 8, further comprising an adjuvant.
11. A therapeutic composition according to claim 10, wherein said adjuvant is selected from collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic.
12. A therapeutic composition according to claim 8, wherein said protein is present in a concentration of from 1 to 50  $\mu\text{g/ml}$  of total volume.

13. A composition according to any one of claims 8 - 12, for use in enhancing the wound-healing process in warm-blooded animals.
- 5 14. A protein according to any one of claims 1 - 7, for use in promoting the growth of mammalian cells by incubating the cells with the protein.
15. A wound dressing containing a protein according to any one of claims 1 - 7.
- 10 16. Use of a protein according to any one of claims 1 - 7 for the manufacture of a medicament for enhancing the wound-healing process in warm-blooded animals.
17. A DNA construct capable of directing the expression and secretion of a protein according to any one of claims 1 - 3 in eucaryotic cells.
- 15 18. A DNA construct according to claim 17, wherein said polypeptide is further characterized by the substitution of at least one cysteine residue at a position corresponding to A-chain position 37, 46 or 47 by another amino acid residue.
- 20 19. A DNA construct capable of directing the expression and secretion of biologically active human PDGF analogs in eucaryotic cells, said DNA construct containing a transcriptional promoter followed downstream by a DNA sequence encoding a polypeptide which is a mosaic of amino acid sequences of the A- and B-chains of human PDGF, wherein said polypeptide is selected from the group consisting of:
  - (a) A-chain amino acids 1-17 joined to B-chain amino acids 24-109;
  - (b) A-chain amino acids 1-31 joined to B-chain amino acids 38-109;
  - 25 (c) A-chain amino acids 1-17 joined to B-chain amino acids 24-97 joined to A-chain amino acids 92-104.
- 30 20. A DNA construct according to claim 19, wherein said polypeptide is further characterized by the substitution of at least one cysteine residue at a position corresponding to B-chain position 43, 52 or 53 by another amino acid residue.
21. A DNA construct according to claim 18 or claim 20, wherein said other amino acid residue is a serine residue.
- 35 22. A DNA construct according to any of claims 17 - 21, wherein said polypeptide does not include an N-linked glycosylation site.
23. A method of preparing biologically active human PDGF analogs, comprising:
  - introducing into a eucaryotic host cell a DNA construct according to any of claims 17 - 22;
  - 40 growing said eucaryotic host cell in an appropriate medium; and
  - isolating the PDGF analog from said eucaryotic host.
24. A method of preparing biologically active human PDGF analogs, comprising:
  - introducing into a eucaryotic host cell a DNA construct according to claim 19;
  - 45 introducing into said eucaryotic host cell a second DNA construct containing a transcriptional promoter followed downstream by a DNA sequence encoding a polypeptide selected from the group consisting of:
    - (a) the A-chain of human PDGF from amino acid 9 to amino acid 104;
    - (b) the A-chain of human PDGF from amino acid 9 to amino acid 95;
    - 50 (c) the A-chain of human PDGF from amino acid 1 to amino acid 95;
    - (d) the A-chain of human PDGF from amino acid 1 to amino acid 104.
    - (e) the B-chain of human PDGF from amino acid 15 to amino acid 109;
    - (f) the B-chain of human PDGF from amino acid 1 to amino acid 101;
    - (g) the B-chain of human PDGF from amino acid 15 to amino acid 101;
    - 55 (h) the B-chain of human PDGF from amino acid 1 to amino acid 109;
  - growing said eucaryotic host cell in an appropriate medium; and
  - isolating the PDGF analog from said eucaryotic host.

## Patentansprüche

1. Ein rekombinantes Protein-Homodimer mit zwei Disulfidgebundenen Polypeptidketten, wobei besagte Ketten ausgewählt sind aus der Gruppe, bestehend aus:  
5       (a) der A-Kette von menschlichem PDGF von Aminosäure 9 bis Aminosäure 104;  
         (b) der A-Kette von menschlichem PDGF von Aminosäure 9 bis Aminosäure 95;  
         (c) der A-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 95 und  
         (d) der A-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 104,  
wobei besagtes Protein die mitogene Aktivität von menschlichem PDGF besitzt.  
10
2. Ein rekombinantes Protein-Homodimer nach Anspruch 1, das weiter gekennzeichnet ist durch das Ersetzen von wenigstens einem Cysteinrest an Position 37, 46 oder 47 durch einen anderen Aminosäurerest.
- 15 3. Ein rekombinantes Protein-Homodimer nach Anspruch 2, wobei besagter anderer Aminosäurerest ein Serinrest ist.
4. Ein rekombinantes Protein mit zwei Disulfid-gebundenen Polypeptidketten, wobei wenigstens eine von besagten Ketten ein Mosaik von Aminosäuresequenzen der A- und B-Ketten von menschlichen PDGF  
20 ist, wobei die Mosaikkette ausgewählt ist aus der Gruppe, bestehend aus:  
         (a) A-Ketten-Aminosäuren 1-17, verknüpft mit B-Ketten-Aminosäuren 24-109;  
         (b) A-Ketten-Aminosäuren 1-31, verknüpft mit B-Ketten-Aminosäuren 38-109;  
         (c) A-Ketten-Aminosäuren 1-17, verknüpft mit B-Ketten-Aminosäuren 24-97, verknüpft mit A-Ketten 92-104;  
25 und wobei die zweite Kette ausgewählt ist aus der Gruppe, bestehend aus:  
         Ketten (a), (b) und (c), wie oben definiert;  
         (d) der A-Kette von menschlichem PDGF von Aminosäure 9 bis Aminosäure 104;  
         (e) der A-Kette von menschlichem PDGF von Aminosäure 9 bis Aminosäure 95;  
         (f) der A-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 95;  
30       (g) der A-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 104;  
         (h) der B-Kette von menschlichem PDGF von Aminosäure 15 bis Aminosäure 109;  
         (i) der B-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 101;  
         (j) der B-Kette von menschlichem PDGF von Aminosäure 15 bis Aminosäure 101; und  
         (k) der B-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 109,  
35 wobei besagtes Protein die mitogene Aktivität von menschlichem PDGF besitzt.
5. Ein rekombinantes Protein nach Anspruch 4, das weiter gekennzeichnet ist durch das Ersetzen von wenigstens einem Cysteinrest an einer Position, die A-Ketten-Position 37, A-Ketten-Position 46, A-Ketten-Position 47, B-Ketten-Position 43, B-Ketten-Position 52 oder B-Ketten-Position 53 entspricht,  
40 durch einen anderen Aminosäurerest.
6. Ein rekombinantes Protein nach Anspruch 5, wobei besagter anderer Aminosäurerest ein Serinrest ist.
7. Ein rekombinantes Protein nach einem der Ansprüche 1-6, wobei besagtes Protein nicht-glykosyliert ist.  
45
8. Eine therapeutische Zusammensetzung, die ein Protein nach einem der Ansprüche 1-7 und einen physiologisch annehmbaren Trägerstoff umfaßt.
9. Eine therapeutische Zusammensetzung nach Anspruch 8, wobei besagter Trägerstoff ausgewählt ist  
50 aus Albumin, sterilem Wasser und physiologischer Kochsalzlösung.
10. Eine therapeutische Zusammensetzung nach Anspruch 8, die außerdem ein Adjuvans umfaßt.
11. Eine therapeutische Zusammensetzung nach Anspruch 10, wobei besagtes Adjuvans ausgewählt ist  
55 aus Kollagen, Hyaluronsäure, Fibronectin, Faktor XIII und einem Antibiotikum.
12. Eine therapeutische Zusammensetzung nach Anspruch 8, wobei besagtes Protein in einer Konzentration von 1 bis 50 µg/ml Gesamtvolumen vorhanden ist.

13. Eine Zusammensetzung nach einem der Ansprüche 8-12, zur Verwendung bei der Verstärkung des Wundheilungsprozesses bei Warmblütern.
- 5 14. Ein Protein nach einem der Ansprüche 1-7, zur Verwendung bei der Förderung des Wachstums von Säugerzellen durch Inkubation der Zellen mit dem Protein.
15. Ein Wundverband, der ein Protein nach einem der Ansprüche 1-7 enthält.
- 10 16. Verwendung eines Proteins nach einem der Ansprüche 1-7 zur Herstellung eines Arzneimittels zur Verstärkung des Wundheilungsprozesses bei Warmblütern.
17. Ein DNA-Konstrukt, das in der Lage ist, die Expression und Sekretion eines Proteins nach einem der Ansprüche 1-3 in eukaryotischen Zellen zu steuern.
- 15 18. Ein DNA-Konstrukt nach Anspruch 17, wobei besagtes Polypeptid weiter gekennzeichnet ist durch das Ersetzen von wenigstens einem Cysteinrest an einer Position, die A-Ketten-Position 37, 46 oder 47 entspricht, durch einen anderen Aminosäurerest.
- 20 19. Ein DNA-Konstrukt, das in der Lage ist, die Expression und Sekretion von biologisch aktiven Analogen zu menschlichem PDGF in eukaryotischen Zellen zu steuern, wobei besagtes DNA-Konstrukt einen Transkriptionspromotor enthält, flußabwärts gefolgt von einer DNA-Sequenz, die ein Polypeptid kodiert, das ein Mosaik von Aminosäuresequenzen der A- und B-Ketten von menschlichem PDGF ist, wobei besagtes Polypeptid ausgewählt ist aus der Gruppe, bestehend aus:
  - 25 (a) A-Ketten-Aminosäuren 1-17, verknüpft mit B-Ketten-Aminosäuren 24-109;
  - (b) A-Ketten-Aminosäuren 1-31, verknüpft mit B-Ketten-Aminosäuren 38-109;
  - (c) A-Ketten-Aminosäuren 1-17, verknüpft mit B-Ketten-Aminosäuren 24-97, verknüpft mit A-Ketten-Aminosäuren 92-104.
- 30 20. Ein DNA-Konstrukt nach Anspruch 19, wobei besagtes Polypeptid weiter gekennzeichnet ist durch das Ersetzen von wenigstens einem Cysteinrest an einer Position, die B-Ketten-Position 43, 52 oder 53 entspricht, durch einen anderen Aminosäurerest.
- 35 21. Ein DNA-Konstrukt nach Anspruch 18 oder Anspruch 20, wobei besagter anderer Aminosäurerest ein Serinrest ist.
22. Ein DNA-Konstrukt nach einem der Ansprüche 17-21, wobei besagtes Polypeptid keine N-verknüpfte Glykosylierungsstelle einschließt.
- 40 23. Ein Verfahren zur Herstellung von biologisch aktiven Analogen von menschlichem PDGF, welches umfaßt:  
Einführen eines DNA-Konstruktes nach einem der Ansprüche 17-22 in eine eukaryotische Wirtszelle;  
Züchten besagter eukaryotischen Wirtszelle in einem geeigneten Medium; und  
Isolieren des PDGF-Analogen aus besagtem eukaryotischen Wirt.
- 45 24. Ein Verfahren zur Herstellung von biologisch aktiven Analogen von menschlichem PDGF, welches umfaßt:  
Einführen eines DNA-Konstruktes nach Anspruch 19 in eine eukaryotische Wirtszelle;  
Einführen eines zweiten DNA-Konstruktes in besagte eukaryotische Wirtszelle, das einen Transkriptionspromotor enthält, flußabwärts gefolgt von einer DNA-Sequenz, die ein Polypeptid kodiert, das ausgewählt ist aus der Gruppe, bestehend aus:
  - 50 (a) der A-Kette von menschlichem PDGF von Aminosäure 9 bis Aminosäure 104;
  - (b) der A-Kette von menschlichem PDGF von Aminosäure 9 bis Aminosäure 95;
  - (c) der A-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 95;
  - (d) der A-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 104;
  - 55 (e) der B-Kette von menschlichem PDGF von Aminosäure 15 bis Aminosäure 109;
  - (f) der B-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 101;
  - (g) der B-Kette von menschlichem PDGF von Aminosäure 15 bis Aminosäure 101;

(h) der B-Kette von menschlichem PDGF von Aminosäure 1 bis Aminosäure 109;  
 Züchten besagter eukaryotischen Wirtszelle in einem geeigneten Medium; und  
 Isolieren des PDGF-Analogen aus besagtem eukaryotischen Wirt.

## 5 Revendications

1. Homodimère de protéine recombiné ayant deux chaînes polypeptidiques liées par des liaisons disulfure, lesdites chaînes étant choisies dans le groupes constitué par:
  - (a) la chaîne A du PDGF humain de l'acide aminé 9 à l'acide aminé 104;
  - 10 (b) la chaîne A du PDGF humain de l'acide aminé 9 à l'acide aminé 95;
  - (c) la chaîne A du PDGF humain de l'acide aminé 1 à l'acide aminé 95; et
  - (d) la chaîne A du PDGF humain de l'acide aminé 1 à l'acide aminé 104, ladite protéine ayant une activité mitogène de PDGF humain.
- 15 2. Homodimère de protéine recombiné selon la revendication 1, caractérisé en outre par la substitution d'au moins un résidu de cystéine en position 37, 46 ou 47 par un autre résidu d'acide aminé.
3. Homodimère de protéine recombiné selon la revendication 2, dans lequel ledit autre résidu d'acide aminé est un résidu de sérine.
- 20 4. Protéine recombinée ayant deux chaînes polypeptidiques liées par des liaisons disulfure, dans laquelle au moins une desdites chaînes est une mosaïque de séquences d'acides aminés des chaînes A et B du PDGF humain, la chaîne mosaïque étant choisie dans le coupe constitué par
  - (a) les acides aminés 1-17 de la chaîne A reliés aux acides aminés 24-109 de la chaîne B;
  - 25 (b) les acides aminés 1-31 de la chaîne A reliés aux acides aminés 38-109 de la chaîne B;
  - (c) les acides aminés 1-17 de la chaîne A reliés aux acides aminés 24-97 de la chaîne B reliés aux acides aminés 92-104 de la chaîne A;
 et la seconde chaîne étant choisie dans le coupe constitué par
  - les chaînes (a), (b) et (c) telles que définies ci-dessus;
  - 30 (d) la chaîne A du PDGF humain de l'acide aminé 9 à l'acide aminé 104;
  - (e) la chaîne A du PDGF humain de l'acide aminé 9 à l'acide aminé 95;
  - (f) la chaîne A du PDGF humain de l'acide aminé 1 à l'acide aminé 95;
  - (g) la chaîne A du PDGF humain de l'acide aminé 1 à l'acide aminé 104,
  - (h) la chaîne B du PDGF humain de l'acide aminé 15 à l'acide aminé 109;
  - 35 (i) la chaîne B du PDGF humain de l'acide aminé 1 à l'acide aminé 101;
  - (j) la chaîne B du PDGF humain de l'acide aminé 15 à l'acide aminé 101; et
  - (k) la chaîne B du PDGF humain de l'acide aminé 1 à l'acide aminé 109, ladite protéine ayant une activité mitogène de PDGF humain.
- 40 5. Protéine recombinée selon la revendication 4, caractérisée en outre par la substitution d'au moins un résidu de cystéine en une position correspondant à la position 37 de la chaîne A, la position 46 de la chaîne A, la position 47 de la chaîne A, la position 43 de la chaîne B, la position 52 de la chaîne B ou la position 53 de la chaîne B par un autre résidu d'acide aminé.
- 45 6. Protéine recombinée selon la revendication 5, dans laquelle ledit autre résidu d'acide aminé est un résidu de sérine.
7. Protéine recombinée selon l'une quelconque des revendications 1 - 6, dans laquelle ladite protéine n'est pas glycosylée.
- 50 8. Composition thérapeutique comprenant une protéine selon l'une quelconque des revendications 1 - 7 et un support physiologiquement acceptable.
9. Composition thérapeutique selon la revendication 8, dans laquelle ledit support est choisi parmi l'albumine, l'eau stérile et une solution salée.
- 55 10. Composition thérapeutique selon la revendication 8, comprenant en outre un adjuvant.

11. Composition thérapeutique selon la revendication 10, dans laquelle ledit adjuvant est choisi parmi le collagène, l'acide hyaluronique, la fibronectine, le facteur XIII et un antibiotique.
- 5 12. Composition thérapeutique selon la revendication 8, dans laquelle ladite protéine est présente à une concentration comprise entre 1 et 50 µg/ml de volume total.
13. Composition selon l'une quelconque des revendications 8 - 12, à utiliser pour renforcer le processus de cicatrisation chez les animaux à sang chaud.
- 10 14. Protéine selon l'une quelconque des revendications 1 - 7, à utiliser pour promouvoir la croissance de cellules de mammifères par incubation des cellules avec la protéine.
- 15 15. Pansement pour blessures contenant une protéine selon l'une quelconque des revendications 1 - 7.
16. Utilisation d'une protéine selon l'une quelconque des revendications 1 - 7 pour la fabrication d'un médicament destiné à renforcer le processus de cicatrisation chez les animaux à sang chaud.
17. Assemblage d'ADN capable de diriger l'expression et la sécrétion d'une protéine selon l'une quelconque des revendications 1 - 3 dans des cellules eucaryotes.
- 20 18. Assemblage d'ADN selon la revendication 17, dans lequel ledit polypeptide est caractérisé en outre par la substitution d'au moins un résidu de cystéine en une position correspondant à la position 37, 46 ou 47 de la chaîne A par un autre résidu d'acide aminé.
- 25 19. Assemblage d'ADN capable de diriger l'expression et la sécrétion d'analogues de PDGF humain biologiquement actifs dans des cellules eucaryotes, ledit assemblage d'ADN contenant un promoteur de la transcription suivi en aval par une séquence d'ADN codant pour un polypeptide qui est une mosaïque de séquences d'acides aminés des chaînes A et B du PDGF humain, ledit polypeptide étant choisi dans le groupe constitué par
- 30 (a) les acides aminés 1-17 de la chaîne A reliés aux acides aminés 24-109 de la chaîne B;  
(b) les acides aminés 1-31 de la chaîne A reliés aux acides aminés 38-109 de la chaîne B;  
(c) les acides aminés 1-17 de la chaîne A reliés aux acides aminés 24-97 de la chaîne B reliés aux acides aminés 92-104 de la chaîne A.
- 35 20. Assemblage d'ADN selon la revendication 19, dans lequel ledit polypeptide est caractérisé en outre par la substitution d'au moins un résidu de cystéine en une position correspondant à la position 43, 52 ou 53 de la chaîne B par un autre résidu d'acide aminé.
- 40 21. Assemblage d'ADN selon la revendication 18 ou la revendication 20, dans lequel ledit autre résidu d'acide aminé est un résidu de sérine.
22. Assemblage d'ADN selon l'une quelconque des revendications 17 - 21, dans lequel ledit polypeptide ne comprend pas de site de glycosylation sur un atome d'azote.
- 45 23. Procédé de préparation d'analogues de PDGF humain biologiquement actifs, comprenant:  
l'introduction dans une cellule hôte eucaryote d'un assemblage d'ADN selon l'une quelconque des revendications 17 - 22;  
la culture de ladite cellule hôte eucaryote dans un milieu approprié; et  
l'isolement de l'analogue de PDGF à partir dudit hôte eucaryote.
- 50 24. Procédé de préparation d'analogues de PDGF humain biologiquement actifs, comprenant:  
l'introduction dans une cellule hôte eucaryote d'un assemblage d'ADN selon la revendication 19;  
l'introduction dans ladite cellule hôte eucaryote d'un second assemblage d'ADN contenant un promoteur de la transcription suivi en aval par une séquence d'ADN codant pour un polypeptide choisi
- 55 dans le groupe constitué par  
(a) la chaîne A du PDGF humain de l'acide aminé 9 à l'acide aminé 104;  
(b) la chaîne A du PDGF humain de l'acide aminé 9 à l'acide aminé 95;  
(c) la chaîne A du PDGF humain de l'acide aminé 1 à l'acide aminé 95;

- (d) la chaîne A du PDGF humain de l'acide aminé 1 à l'acide aminé 104;  
(e) la chaîne B du PDGF humain de l'acide aminé 15 à l'acide aminé 109;  
(f) la chaîne B du PDGF humain de l'acide aminé 1 à l'acide aminé 101;  
(g) la chaîne B du PDGF humain de l'acide aminé 15 à l'acide aminé 101; et  
5 (h) la chaîne B du PDGF humain de l'acide aminé 1 à l'acide aminé 109,  
la culture de ladite cellule hôte eucaryote dans un milieu approprié; et  
l'isolement de l'analogue de PDGF à partir dudit hôte eucaryote.

10

15

20

25

30

35


40

45

50

55

FIG. 1A



Hph I  
 CT ATG ACC CTC ACC TGG CAG GGG GAC CCC ATT CCT GAG GAG CTC TAT AAG ATG  
 MET Thr Leu Thr Trp Gln Gly Asp Pro Ile Pro Glu Glu Leu Tyr Lys MET

367 382 397  
 v-sis-helper viral junction

412 427 442 Pst I 457  
 CTG AGT GGC CAC TCG ATT CGC TCC TTC AAT GAC CTC CAG CGC CTG CTG CAG GGA  
 Leu Ser Gly His Ser Ile Arg Ser Phe Asn Asp Leu Gln Arg Leu Leu Gln Gly

472 487 502  
 GAG TCC GGA AAA GAA GAT GGG GCT GAG CTG GAC CTG AAC ATG ACC CGC TCC CAT  
 Asp Ser Gly Lys Glu Asp Gly Ala Glu Leu Asp Leu Asn MET Thr Arg Ser His

517 532 547 562  
 TCT GGT GGC GAG CTG GAG AGC TTG GCT CGT GGG AAA AGG AGC CTG GGT TCC CTG  
 Ser Gly Gly Glu Leu Glu Ser Leu Ala Arg Gly Lys Arg Ser Leu Gly Ser Leu

577 592 607  
 AGC GTT GCC GAG CCA GCC ATG ATT GCC GAG TGC AAG ACA CGA ACC GAG GTG TTC  
 Ser Val Ala Glu Pro Ala MET Ile Ala Glu Cys Lys Thr Arg Thr Glu Val Phe

Bgl II  
 622 637 652 667  
 GAG ATC TCC CGG CGC CTC ATC GAC CGC ACC AAT GCC AAC TTC CTG GTG TGG CCG  
 Glu Ile Ser Arg Arg Leu Ile Asp Arg Thr Asn Ala Asn Phe Leu Val Trp Pro

FIG. 1B

```

      682      697      712      727
CCC TGC GTG GAG GTG CAG CGC TGC TCC GGC TGT TGC AAC AAC CGC AAC GTG CAG
Pro Cys Val Glu Val Gln Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln

      742      757      772
TGC CGG CCC ACC CAA GTG CAG CTG CGG CCA GTC CAG GTG AGA AAG ATC GAG ATT
Cys Arg Pro Thr Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile

      787      802      817      832
GTG CGG AAG AAG CCA ATC TTT AAG AAG GCC ATG GTG ACG CTG GAG GAC CAC CTG
Val Arg Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu

      847      862      877
GCA TGC AAG TGT GAG ATA GTG GCA GCT GCA CGG GCT GTG ACC CGA AGC CCG GGG
Ala Cys Lys Cys Glu Ile Val Ala Ala Ala Arg Ala Val Thr Arg Ser Pro Gly

      892      907      922      937
ACT TCC CAG GAG CAG CGA GCC AAA ACG ACC CAA AGT CGG GTG ACC ATC CGG ACG
Thr Ser Gln Glu Gln Arg Ala Lys Thr Thr Gln Ser Arg Val Thr Ile Arg Thr

      952      967      982      997
GTG CGA GTC CGC CGG CCC CCC AAG GGC AAG CAC CGG AAA TGC AAG CAC ACG CAT
Val Arg Val Arg Arg Pro Pro Lys Gly Lys His Arg Lys Cys Lys His Thr His

      1012      1027      1043      1053
GAC AAG ACG GCA CTG AAG GAG ACC CTC GGA GCC TAA GGGCATCGGC AGGAGAATAT
Asp Lys Thr Ala Leu Lys Glu Thr Leu Gly Ala

      1063      1073      1083      1093      1103      1113      1123
GGGCAGCGGG TCTCCTGCCA GCGGCCTCCA GCATCTTGCC CAGCAGCTCA AGAAGAGAAA AAAGGACTGA

      1133      1143      1153      1163      1173      1183      1193
ACTCCACCAC CATCTTCTTC CCTTAACCTCC AAAAAGTTGA AATAAGAGTG TGAAAGAGAC TGATAGGGTC

      1203      1213      1223      1233      1243      1253      1263
GCTGTTTGAA AAAAAGTGGC TCCTTCCTCT GCACCTGGCC TGGGCCACAC CCAAGTGCTG TGGACTGGCC

      1273      1283      1293      1303      1313      1323      1333
CGAGGGGCCC TGCACGTGGC CCTGAGCACC TCTCAGTGTA GCCTGCCTGG TCCCTAGACC CCTGGCCAGC

      1343      1353      1363      1373
TCCAAGGGGA GGCACCTCCA GGCAGGCCAG GCTACCTCGG GGGTCTAG
XbaI v-sis-helper viral junction

```

FIG. 1B





FIG. 2

FIG. 3






FIG. 4

FIG. 5




FIG. 6





FIG. 7






FIG. 8

FIG. 9




FIG. 10

